Mechanisms of Inhibition and Contraction in Uterine Smooth Muscle by Al-Zadjali, Khamis Hussain
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
MECHANISMS OF INHIBITION AND CONTRACTION
IN UTERINE SMOOTH MUSCLE
A thesis presented for the degree of Doctor of Philosophy 
in the University of Glasgow
by
K.H. AL-ZADJALI, B.Sc., M.B.B.S. (Karachi)
C-*'"
Department of Pharmacology,
University of Glasgow,
Glasgow G12 8QQ. December 1988
ProQuest Number: 10999325
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10999325
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
iTABLE OF CONTENTS
Page No.
List of Tables 1
List of Figures and Plate 4
Acknowledgements 14
Publications 15
Summary 16
Abbreviations 19
INTRODUCTION
A. Hormonal control of uterine function 
during the oestrous cycle, pregnancy
and parturition 20
B. Uterine response to catecholamines during
the oestrous cycle, pregnancy and in 
parturition 22
(i) Effect of ovarian hormones on uterine 
response to catecholamines 24
(ii) Effect of agonists removal mechanisms
on uterine response to catecholamines 26
C. Intracellular mechanisms involved in uterine
response to catecholamines 27
(i) Role of ion conductance and channel 
activity 27
(ii) Role of cyclic nucleotides 29
D. Involvement of prostaglandins in the excitatory
and inhibitory effects of catecholamines 32
METHODS
A. Animals 37
B. Virgin rats - vaginal smears 37
C. Pregnant and post partum rats 40
D. Isolated uterine horn preparations 40
(i) Virgin rats
(ii) Pregnant and post partum rats
Motor responses to acetylcholine
Experiments on uteri from non pregnant rats
(i) Experiments on uteri ‘in the four stages 
of the oestrous cycle
Inhibitory responses to adrenoceptor agonists
(1) alone
(2) in presence of an CX - adrenoceptor 
antagonist
(3) in presence of inhibitors of neuronal 
and extraneuronal uptake mechanisms
(4) in the combined presence of an ^  
adrenoceptor antagonist and inhibitors 
of neuronal and extraneuronal mechanisms
(5) in presence of an inhibitor of cyclo- 
oxygenase
(ii) Experiments on uteri from oestrogen 
pre-treated rats
Inhibitory responses to adrenoceptor 
agonists:-
(1) alone
(2) in presence of an inhibitor of cyclo- 
oxygenase
(3) in presence of an inhibitor of phospho- 
lipase A2
(4) in presence of an inhibitor of cyclo- 
oxygenase and arachidonic acid
Experiments on uteri from 20 day pregnant and
one day post-partum rats
(i) Experiments on uterine preparations with 
the endometrium present
Inhibitory responses to adrenaline and 
salbutamol in presence of an inhibitor of 
cyclo-oxygenase
(ii) Experiments on uterine preparations 
with endometrium removed
Inhibitory responses to adrenaline and 
salbutamol in presence of an inhibitor 
of cyclo-oxygenase.
H. Measurement of adenosine 3'5! cyclic mono­
phosphate content in the uterus
(i) Extraction of tissue cAMP
(ii) Assay of cAMP
(1) Preparation of standard cAMP solution
(2) Assay procedure
(3) Preparation of a standard curve for 
cAMP assay
(iii) Measurement of basal tissue cAMP in the 
four phases of the oestrous cycle
(iv) Effects on basal cAMP levels of:-
(1) Salbutamol
(2) a cyclooxygenase inhibitor
(3) salbutamol in presence of a cyclo- 
oxygenase inhibitor
(v) Measurement of basal tissue cAMP in 
20 day pregnant rat uterus with and 
without endometrium
(vi) Effect of salbutamol on basal cAMP 
levels
I. CHEMICALS AND DRUGS 
J. STATISTICS 
RESULTS
I. Isolated uterine horn preparations
A. Responses to acetylcholine
IV
Page No
B. Responses to adrenoceptor agonists in
the four phases of the oestrous cycle 59
C. Responses to adrenoceptor agonists
in the presence of an OC -receptor
antagonist and uptake inhibitors in
the four phases of the oestrous cycle 78
1. Motor responses 78
2. Inhibitory responses to NA, ADR and 
SAL in the presence of an D< -
receptor antagonist 79
3. Inhibitory responses to NA, ADR and 
SAL in the presence of inhibitors of 
neuronal and extra-neuronal uptake 
mechanisms 83
4. Inhibitory responses to NA, ADR and 
SAL in the combined presence of both 
an -receptor antagonist and
inhibitors of neuronal and extra­
neuronal uptake mechanisms 88
D. Responses to &  -adrenoceptor agonists 
in the presence of a cyclooxygenase
inhibitor 93
E. Inhibitory responses to salbutamol in 
the presence of a cyclo-oxygenase 
inhibitor in the four phases of the
oestrous cycle. 93
F. Responses to a ^  -adrenoceptor agonist
in oestrogen pretreated animals 104
1. Inhibitory responses to salbutamol, 
isoprenaline and isoxsuprine in uteri 
from oestrogen pretreated animals 105
G. Responses to a &  -adrenoceptor agonist
in the presence of a phospholipase A2 
inhibitor 110
H. Responses to a /* -adrenoceptor agonist
in the combined presence of a cyclo- 
oxygenase inhibitor and arachidonic acid 112
I. Responses to adrenoceptor agonists in
uteri from 20-day pregnant animals 114
V1. Inhibitory responses to adrenaline 
and salbutamol
2. Inhibitory responses to adrenaline 
and salbutamol in the presence of 
a cyclo-oxygenase inhibitor
J. Responses to adrenoceptor agonists in 
uteri from one-day post-partum animals
1. Inhibitory responses to adrenaline 
and salbutamol
2. Inhibitory responses to adrenaline 
and salbutamol in the presence of a 
cyclo-oxygenase inhibitor
K. Responses to adrenoceptor agonists in 
endometrium-free uteri from 20-day 
pregnant animals
1. Inhibitory responses to adrenaline and 
salbutamol in endometrium-free uteri
2. Inhibitory responses to adrenaline and 
salbutamol in the presence of a cyclo- 
oxygenase inhibitor
L. Responses to adrenoceptor agonists in 
endometrium-free uteri from one-day 
post-partum animals
1. Inhibitory responses to adrenaline and 
salbutamol
2. Inhibitory responses to adrenaline and 
salbutamol in the presence of a cyclo- 
oxygenase inhibitor
M. Adenosine 3'5' cyclic monophosphate assay 
experiments in uteri from non-pregnant and 
pregnant animals
1. cAMP levels in uteri from the four 
phases of the oestrous cycle
2. cAMP levels in uteri from 20-day 
pregnant animals
Page No.
114
114
124
124
124
128
134
138
144
144
148
154
154
161
v i
Page No.
DISCUSSION
A. Responses to acetylcholine in uteri during 
the oestrous cycle, pregnancy and in 
post-partum animals 163
B. Responses to adrenoceptor agonists in 
the oestrous cycle and after oestrogen 
pretreatment 164
C. Effect of adrenoceptor agonists on
intramural prostaglandin production 170
D. Role of cAMP 178
REFERENCES 18 2
= ■ ? > .i .■ - - ' : V X  . J
y- i x ute.r.i f/rxm thxz
■■ d ; '  d r : , ; - . ; ' : ;  I y 7 y ;
x x r e y t  i v s  ( v v ;v
is 1 x n e  ’ jy v v  v : - v  7. v X: x. v w
23
4
5
6
7
8
9
10
11
12
LIST OF TABLES
Title Page No
Ovarian events, gross appearance of
uterus and vaginal histology of rats during
the oestrous cycle. 38
Composition of Tyrode solution (mmol/1). 42
Maximum tension developed to acetylcholine 
(Ach) and potency in nonpregnant, pregnant 
and post partum rat uteri. 60
Noradrenaline potency in uteri from the 
four phases of the oestrous cycle (pD2 
values). 66
Adrenaline potency in uteri from the four 
phases of the oestrous cycle (pD2 values) 71
Salbutamol potency in uteri from the four 
phases of the oestrous cycle (pD2 values). 77
Effect of azapetine (AZA, 10“6 M) on
noradrenaline potency in uteri from the four 
phases of the oestrous cycle (pD2 values). 80
Effect of azapetine (AZA, 10”6 M) on
adrenaline potency in uteri from the four 
phases of the oestrous cycle (pD2 values). 81
Effect of azapetine (AZA, 10“6 M) on
Salbutamol potency in uteri from the four 
phases of the oestrous cycle. 82
Effect of desipramine (DMI, 10~6 M)
and normetanephrine (NMN, 10“ M) on
noradrenaline potency in uteri from the
four phases of the oestrous cycle
(pD2 values). 84
Effect of desipramine (DMI, 10”6 M ) 
and normetanephrine (NMN, 10 M) on
adrenaline potency in uteri from the four 
phases of the oestrous cycle (pD2 values). 85
Effect of desipramine (DMI, 10""6 M) 
and normetanephrine (NMN, 10 M) on 
salbutamol potency in uteri from the four 
phases of the oestrous cycle (pD2 values). 87
1
Table Title Page No.
13 Effect of azapetine (AZA, 10“6 MO,
desipramine (DMI, 10 Ml and
normetanephrine NMN, 10 M) on 
noradrenaline potency in uteri from 
the four phases of the oestrous cycle 
(pD2 values).
14 Effect of azapetine (£ZA, 10-6 M),
desipramine (DMI, 10 M)_ and
normetanephrine (NMN, 10-6 M), on 
adrenaline potency in uteri from the 
four phases of the oestrous cycle 
(pD2 values).
15 Effect of azapetine (AZA, 10-6 M),
desipramine (DMI, 10~6 M) and 
normetanephrine (NMN, 10“6 M) on 
salbutamol potency in uteri from the 
four phases of the oestrous cycle (pD2 
values).
16 Effect of flurbiprofen (FBF, 10 M)
on salbutamol potency in uteri from the 
four phases of the oestrous cycle (pD2 
values).
17 Effect of flurbiprofen (FBF, 10~5 M)
on SAL, ISO and ISOX potencies in uteri 
from oestrogen pretreated animals (pD2 
values).
18 Adrenaline and salbutamol potency in uteri
from 20-day pregnant animals (pD2 values).
19 Effect of flurbiprofen (FBF, 10“5 M) on
ADR and SAL potency in uteri from 20-day 
pregnant animals (pD2 values).
20 Adrenaline and salbutamol potency in uteri
from one-day post partum animals
(pD2 values).
21 Effect of flurbiprofen (FBF, 10~5 M) on
ADR and SAL potencies in uteri from one-day 
post partum animals (pD2 values).
22 Effect of endometrium removal on ADR and SAL
potencies in uteri from 20-day pregnant 
animals (pD2 values).
89
91
92
102
109
117
123
127
133
137
2
Table Title Page No.
23 Effect of flurbiprofen (FBF, 10~5 M)
on ADR and SAL potencies in endometrium-
free uteri from 20-day pregnant animals 
(pD2 values). 143
24 Effect of endometrium removal on ADR and
SAL potencies in uteri from one-day
post partum animals (pD2 values). 147
25 Effect of flurbiprofen (FBF, 10”5 M)
on ADR and SAL potencies, in endometrium-
free uteri from one-day post partum 
animals (pD2 values). 153
3
Figure
2
3
4
5
6
LIST OF FIGURES 
Title Page No.
Log. concentration response curves to 
noradrenaline in the rat isolated uterus 
in proestrus: controls, and effects of 
azapetine (10“6 M), desipramine 62
(10“6 M) and normetanephrine (10-  ^M ).
Log. concentration response curves to 
noradrenaline in the rat isolated uterus 
in oestrus: control, and effects of 
azapetine (10“6 M), desipramine (10-6M) 
and normetanephrine (10-6 M) . 63
Log. concentration response curves to 
noradrenaline in the rat isolated uterus
in metoestrus: controls, and effects of
— fi —fiazapetine (10 M), desipramine (10 M)
and normetanephrine (10 M). 64
Log. concentration response curves to
noradrenaline in the rat isolated uterus in
dioestrus: controls, and effects of
azapetine (10“6 M), desipramine (10-6 M)
and normetanephrine (10-6 M ) . 65
Log. concentration response curves to
adrenaline in the rat isolated uterus in
proestrus: controls, and effects of
azapetine (10“6 M, desipramine
(10“6 M) and normetanephrine (10-6 M ) . 67
Adenosine 3'5f cyclic monophosphate standard curve.5 5 3
4
Figure Title Page
7 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
oestrus: controls, and effect of
azapetine (10”6 M), desipramine (10“6 M) 
and normetanephrine (10~6 M). 68
8 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
metoestrus: controls, and effect of
azapetine (10“6 M) , desipramine (10""6 M)
and normetanephrine (10 M). 69
9 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
dioestrus: controls, and effect of
azapetine (10-6 M), desipramine (10-6 M)
• — fiand normetanephrine (10 M) . 70
10 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
proestrus: controls, and effect of
azapetine (10"*6 M) , desipramine (10-6 M) 
and normetanephrine (10“6 M) . 73
11 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
oestrus: controls, and effect of
azapetine (10“6 M), desipramine (10-6 M)
• -fiand normetanephrine (10 M ) . 74
12 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
metoestrus: controls, and effect of
5
Title
azapetine (10“6 M, desipramine (10“6 M)
and normetanephrine (10“6 M ) .
Log. concentration response curves to
salbutamol in the rat isolated uterus in
dioestrus: controls, and effects of
azapetine (10“6 M) , desipramine (10“6 M)
— 6and normetanephrine (10 M ) .
Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
proestrus: controls, and effects of 
flurbiprofen (10-5 M) .
Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
proestrus: Control II, and effects of
flurbiprofen (10“5 M) .
Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
oestrus: controls, and effects of
flurbiprofen (10”5 M).
Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
oestrus: Control II, and effects of
flurbiprofen (10-5 M).
Log. concentration response curves to 
Salbutamol in the rat isolated uterus in 
metoestrus: controls, and effects of
flurbiprofen (10"5 M).
Figure PageTitle
20 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
metoestrus: Control II, and effects of
flurbiprofen (10“5 M). 99
21 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
dioestrus: controls, and effects of
flurbiprofen (10~5 M). 100
22 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
dioestrus: Control II, and effects of
flurbiprofen (10-5 M). 101
23 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
oestrogen pretreated: controls, and
effects of flurbiprofen (10“5 M ) . 106
24 Log. concentration response curves to
isoprenaline in the rat isolated uterus 
in oestrogen pretreated: controls, and 
effects of flurbiprofen (10“5 M ) . 107
25 Log. concentration response curves to
Isoxsuprine in the rat isolated uterus 
in oestrogen pretreated: controls, and 
effects of flurbiprofen (10~5 M). 108
26 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
oestrogen pretreated: controls, and
effects of Quinacrine (10“5 M). Ill
7
Figure Title Page
27 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
oestrogen pretreated: controls, effects
of flurbiprofen (10-5 M) and arachidonic
acid (10~6 M) . 113
28 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
2 0 day pregnant: Control I and Control
II. 115
29 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
20 day pregnant: Control I and Control
II. 116
30 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
20 day pregnant: controls, and effects
of flurbiprofen (10-5 M) . 119
31 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
20 day pregnant: Control II, and effects
of flurbiprofen (10“5 M) . 120
32 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
20 day pregnant: controls, and effects
of flurbiprofen (10~5 M) . 121
33 Log. concentration response curves to
salbutamol in the rat isolated uterus in
8
F igure Table Page
20 day pregnant: Control II, and effects 
of flurbiprofen (10-5 M) . 122
34 Log. concentration response curves to
adrenaline in the rat isolated uterus in
1 day post-partum: Control I and Control
II. 125
35 Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
1 day post-partum: Control I and Control
ii. 126
36 Log. concentration response curves to 
adrenaline in the rat isolated uterus in 
1 day post-partum: controls, and effects
of flurbiprofen (10-5 M). 129
37 Log. concentration response curves to 
adrenaline in the rat isolated uterus in 
1 day post-partum: Control II, and
effects of flurbiprofen (10-5 M). 130
38 Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
1 day post-partum: controls, and effects
of flurbiprofen (10""5 M) . 131
39 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
1 day post-partum: Control II, and
effects of flurbiprofen (10“5 M). 132
40 Log. concentration response curves to 
adrenaline in the rat isolated uterus in
9
Figure Title Page
20 day pregnant: controls, with and
without endometrium. 135
41 Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
20 day pregnant: controls, with and
without endometrium. 136
42 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
20 day pregnant: controls endometrium 
free, and effects of flurbiprofen (10-5
M) . 139
43 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
20 day pregnant endometrium free,
Control II and effects of flurbiprofen
(10“5 M). 140
44 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
20 day pregnant endometrium free,
Control II and effects of flurbiprofen
(10~5 M). 141
45 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
20 day pregnant: controls, endometrium
free, and effects of flurbiprofen (10”5 
M) . 142
10
F igure Title Page
46 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
1 day post-partum: controls, with and
without endometrium. 145
47 Log. concentration response curves to
salbutamol in the rat isolated uterus in 
1 day post partum: controls, with and
without endometrium. 146
48 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
1 day post partum: controls, endometrium 
free, and effects of flurbiprofen (10
M ) . 149
49 Log. concentration response curves to
adrenaline in the rat isolated uterus in 
1 day post-partum endometrium free,
Control II and effects of flurbiprofen
(10~5 M ) . 150
50 Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
1 day post-partum: controls, endometrium 
free, and effects of flurbiprofen (10-5
M ) . 151
51 Log. concentration response curves to 
salbutamol in the rat isolated uterus in 
1 day post-partum endometrium free,
Control II, and effects of flurbiprofen
(10“5 M). 152
11
Title
Effect of flurbiprofen (10“5 M) on basal 
cAMP levels in the rat isolated uterus 
in proestrus, oestrus, metoestrus and 
dioestrus, controls*
Effect of salbutamol on cAMP levels in 
the rat isolated uterus in proestrus: in 
the concentration range (10 M - 
10“5 M ) .
Effect of salbutamol on cAMP levels in 
the rat isolated uterus in oestrus: in
_Q
the concentration range (10 M - 
10~5 M ) .
Effect of salbutamol on cAMP levels in 
the rat isolated uterus in metoestrus:
. — 9m  the concentration range (10 M to 
10-5 M ) .
Effect of salbutamol on cAMP levels in
the rat isolated uterus in dioestrus: in
— 9the concentration range (10 M to 
10~5 M).
Effect of salbutamol on cAMP levels in 
the rat isolated uterus in 20 day
pregnant with and without endometrium in
— 9the concentration range (10 M to
Plate Number 
1
PLATE
Title
Vaginal smears from the four 
phases of the oestrous cycle.
Page No. 
39
13
ACKNOWLE DGEMENTS
I am very thankful to a number of well meaning people 
who made the completion of this project possible. First of 
all, thanks to Professor J.S. Gillespie, who gave me the 
opportunity to work in this prestigious Pharmacology 
Department. I am also grateful to my direct supervisor, Dr 
Frances Boyle for initiating this project.
Other members of the academic staff were also helpful: 
Dr D. Pollock, for his advice, and all members of the 
technical staff were exceedingly helpful to me in both 
personal and material terms. I thank Mr J. Thomson, Ian 
and Robert for the technical assistance. I also 
acknowledge my thanks to Mr Keith Morrison and Stephan 
Boyle.
I am equally grateful to my entire family for their 
support during my stay in Glasgow.
I will seize this opportunity to thank Mrs Lorna 
Peedle of the Anatomy Department for her excellent 
secretarial assistance.
14
PUBLICATIONS
(a) BOYLE, F.C. & AL-ZADJALI, K.H. (1988)
Involvement of prostaglandins in uterine 
inhibitory responses to adrenoceptor agonists in 
pregnant and post-partum rats.
Br. J. Pharmac., 69IP.
15
SUMMARY
SUMMARY
The possible mechanisms involved in the variation in 
rat uterine response to adrenoceptor agonists in 
preparations under different hormonal conditions have 
been investigated during the natural oestrous cycle and 
in pregnant and post-partum animals using 
pharmacological and biochemical techniques.
Uterine tone was induced with acetylcholine (Ach) in 
isolated preparations from non-pregnant and pregnant 
animals. Tension developed to Ach was more than two­
fold higher in uteri from 20-day and 1-day post-partum 
animals than in those from the four phases of the 
oestrous cycle. The observed variation in uterine 
response to Ach may reflect changes that occur in the 
thickness of the myometrium under the different 
hormonal states.
Noradrenaline (NA), adrenaline (ADR), isoprenaline 
(ISO) and isoxsuprine (ISOX) produced inhibitory 
responses in uteri from non-pregnant and pregnant 
animals. During the oestrous cycle, the effects 
elicited by NA, ADR and SAL varied with the phase of 
the cycle. This variation could be partially due to 
the activation of CK -excitatory receptors (NA and ADR) 
and/or to alterations in agonists removal mechanisms 
during the oestrous cycle.
Pre-treatment of animals with oestradiol- 17/6 increased 
the uterine response to SAL when compared to effects
17
observed in natural oestrus indicating a role for the 
ovarian hormones in regulating adrenoceptor function in 
this preparation.
(5) Inhibition of cyclo-oxygenase activity with 
flurbiprofen (FBF) enhanced uterine inhibitory response 
to the adrenoceptor agonists in preparations from non­
pregnant, pregnant and post partum animals suggesting 
that intramurally generated prostaglandins were 
involved in their response. The effect elicited by FBF 
was, however, not reversed by excess exogenous 
arachidonic acid. Inhibition of phospholipase A 2 
activity with quinacrine also enhanced uterine 
inhibitory response to the adrenoceptor agonists.
(6) Removal of the endometrium slightly reduced uterine 
response to ADR and SAL with the effects being 
greater in 1-day post-partum than in 2 0-day pregnant 
animals. In endometrium-free preparations, FBF had no 
significant effect on adrenoceptor agonists responses 
which would tend to suggest that the endometrium may 
play a role as a major source of PGs in the interaction 
between these agonists and the cyclo-oxygenase pathway 
leading to prostaglandin production.
(7) Biochemical measurements of uterine adenosine 3',5' 
cyclic monophosphate (cAMP) were made in uteri from 
non-pregnant and pregnant animals. During the oestrous 
cycle, basal cAMP levels were similar in uteri from the 
four phases and cyclo-oxygenase inhibition with FBF had
no effect on these levels nor on the ability of SAL to 
increase tissue cAMP content. Thus it would appear 
that cAMP may not be involved in the variation in 
uterine response to adrenoceptor agonists during the 
oestrous cycle.
Removal of the endometrium in uteri from 20-day 
pregnant animals did not alter basal tissue cAMP 
content neither did it affect the ability of SAL to 
increase cAMP levels. An effect on tissue cAMP 
metabolism may, therefore, not account for the observed 
changes in uterine response to adrenoceptor agonists in 
endometrium-free preparations.
In conclusion, presence of a heterogeneous population 
of adrenoceptors, an avid agonist removal mechanism, 
ovarian hormones and intramurally generated 
prostaglandins appear to contribute to the observed 
variations in uterine responses to adrenoceptor 
agonists during the oestrous cycle. cAMP is not the 
source of the variation. Adrenoceptor agonists effect 
on intramural prostaglandin production could play an 
important role in their overall response in the rat 
uterus since such an interaction was also present in 
preparations from pregnant and post-partum animals.
ABBREVIATIONS
Ach Acetylcholine
A.A. Arachidonic acid
ADR Adrenaline
AZA Azapetine
cAMP Adenosine 3'5' cyclic monophosphate
DMI Desmethylimipramine
EC50 Concentration producing 50% of the maximum
response
EDTA Ethylene diamine tetra-acetic acid
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NA Noradrenaline
pD2 Negative logarithm to the base 10 of the EC50
QUIN Quinacrine
SAL Salbutamol
TCA Trichloroacetic acid
CHAPTER 1 
INTRODUCTION
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A. HORMONAL CONTROL OF UTERINE FUNCTION DURING THE OESTROUS 
CYCLE. PREGNANCY AND IN PARTURITION
The ovarian hormones, oestrogen and progesterone exert 
profound changes in uterine anatomy and physiology during 
the oestrous cycle, pregnancy and parturition (Brody & 
Wiqvist, 1961; Silva, 1966; Naftalin, Phear & Goldberg,
1973). The uterotrophic effects of the ovarian hormones 
are manifested in terms of hypertrophy and hyperplasia of 
cells. During the oestrous cycle, the cyclical production 
of the ovarian hormones (Yoshinaga, Hawkins & Stocker, 
1969; Butcher, Collins & Fugo, 1974; Brenner & West, 1975) 
is accompanied by either an increase (as in oestrus) or a 
decrease (as in dioestrus) in the size of the myometrium 
(Naftalin et al.. 1973; Digges, 1980).
There is evidence that the changes in the ovarian
3«f
hormones that precede labour initiate^unctions formation in 
the myometrium (Garfield, Kannan & Daniel, 1980; Mackenzie, 
Puri & Garfield, 1983). The presence of gap junctions 
between uterine muscle cells has been shown to be limited 
exclusively to the period just before, during and 
immediately following normal and premature parturition 
(Garfield et al. . 1980; Mackenzie et al. . 1983). It is
possible that the absence of gap junctions between smooth 
muscle cells throughout gestation may maintain pregnancy by 
limiting electrical or metabolic communications between 
cells, thereby preventing coordinated contractions of the 
uterus (Garfield, 1985). Prostaglandins may also play a 
role in the formation of gap junctions since inhibitors of
21
prostaglandin synthesis such as indomethacin have been 
shown to prevent their development (Garfield, Kannan & 
Daniel, 1980).
The adrenergic and cholinergic autonomic neurones 
which innervate the rat uterus appear to be under hormonal 
control. During the oestrous cycle, the density of 
autonomic innervation is greater in oestrus than in 
dioestrus, whilst an intermediate number of these nerves 
occur in proestrus and metoestrus (Adham & Schenk, 19 69).
The transmitter content of myometrial adrenergic
neurones can also be influenced by the ovarian hormones
resulting in its cyclical variation during the oestrous
cycle and pregnancy (Sjoberg, 1967; Hervonen, Kanvera &
Lietzen, 1973). Marshall (1981) found that the ovarian
hormones also affected neurotransmitter turnover of uterine
adrenergic neurones and their overall neuronal activity.
The capacity of the rat uterus to accumulate catecholamines
from the circulation can be influenced by the ovarian
hormones. Wurtman, Chu and Axelrod (1963) found that
after systemic injections of [^H]-labelled catecholamines,
uteri isolated from animals during the oestrus phase of the
oestrous cycle bound more [ H]-adrenaline than those m
3dioestrus, whilst the binding of [ H]-noradrenaline was
reduced. Green and Miller (1966a,b) confirmed and extended 
these findings leading to their proposal that the cyclic 
variation in uterine adrenaline content could result from 
differences in the ratio of adrenaline to noradrenaline in
22
the plasma, and in the altered ability of the uterus, to 
bind these amines. By affecting the capacity of the uterus 
to accumulate catecholamines, the ovarian hormones may 
indirectly modulate stores of these amines. Uterine 
adrenaline, but not noradrenaline stores appear to be 
sensitive to regulation by oestrogen and progesterone 
(Rudzik & Miller, 1962; Falck, Gardmark, Nybell, Owman, 
Rosengren & Sjoberg, 1974).
In summary, the ovarian hormones appear to produce 
marked effects on uterine anatomy and physiology during the 
oestrous cycle, pregnancy and parturition.
B. UTERINE RESPONSE TO CATECHOLAMINES DURING THE OESTROUS 
CYCLE. PREGNANCY AND IN PARTURITION
Responses of the uterus to adrenoceptor agonists vary 
with species and, in some species, with different states of 
hormonal influence (Marshall, 1970). In his first 
classification of the adrenoceptors in the body, Ahlquist 
found excitation to be generally associated with activation 
of cK -adrenoceptors, and inhibition with activation of 
-adrenoceptors (Ahlquist, 1948, 1962). Ahlquist (1962)
classified rat uterine adrenoceptors as belonging to the 
/^-subtype. The classification of rat uterine
adrenoceptors is, however, no longer tenable in view of 
subsequent demonstration by other workers of the presence 
of o( -excitatory receptors in this organ (Diamond & Brody, 
1966; Krall, Mori, Tuck, Le Shon & Korenman, 1978; Boyle & 
Digges, 1982; Boyle & Ohia, 1984; Acritopoulou-Fourcroy,
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Clabaut & Schrub, 1985). Evidence, however, exists which 
suggests that the o( -adrenoceptor population in the rat 
uterus may subserve an inhibitory function (Jensen & 
Vennerod, 1961; Rudzik & Miller, 1962). However the 
adrenoceptor antagonists employed in these studies have 
since been reported to produce non-specific excitatory 
effects on uterine smooth muscle (Tothill, 1967; Paton, 
1968). In the circular muscle of the pregnant rat 
myometrium, CK -receptors predominate and noradrenaline 
increases spontaneous contractions (Chow & Marshall, 1981). 
In the preparturient rat myometrium, the relative 
population of CK  ^ and ^  2-suktypes was assessed by 
studying competition between [3H]-dihydroergocryptine and 
selective agonists and antagonists, or by using [ H ] — 
prazosin and [ H]-rauwolscme (Maltier & Legrand, 1985) 
The results indicated that the membrane fraction obtained 
from a mixture of longitudinal and circular muscles 
contained 45% CX ^-receptors and 55% 2 “recePtors• Thus
it would appear that uterine preparations from rats, as in 
those from other species, contains ex' -adrenoceptors which 
subserve an excitatory function.
The occurrence of -inhibitory receptors in uteri
from non-pregnant and pregnant rats has been generally 
accepted (Diamond & Brody, 1966; Miller, 1967; Krall et al. 
1978; Chow & Marshall, 1981; Boyle & Digges, 1982a,b; 
Acritopoulou-Fourcroy et al, 1985). Rat uterine
adrenoceptors were further subclassified by Lands, Ludena
and Bazzo (1967) into the ft 2 and 2~ca^e9ory* However, 
fa ^ and 2 "Adrenoceptors have been shown to co-exist
in the rat uterus depending on the hormonal condition 
(Richardson & Nahorski, 1978; Nahorski, 1981; Morrison, 
Nimmo & Whitaker, 1987; Ohia & Boyle, 1987).
(i) EFFECT OF THE OVARIAN HORMONES ON UTERINE RESPONSE TO
CATECHOLAMINES
The ovarian hormones, oestrogen and progesterone can 
influence uterine response to catecholamines via an effect 
on adrenoceptor activity.
The overall effect elicited by the hormones depends on 
the species studied. For example, in the longitudinal 
muscle of the virgin cat uterus, -inhibition is
dominant, whereas in the same muscle of pregnant cat cx 
excitation is dominant (Dale, 1906; Bulbring, Casteels and 
Kuriyama, 19 68). In contrast, pregnant rat uterus has few 
CX -adrenoceptors and &  -inhibition is dominant 
(Marshall, 1967). During the middle stage of gestation, 
the longitudinal muscle cells of the rat uterus possess 
mainly -adrenoceptors, while in the circular muscle
cells, ex -adrenoceptors predominate (Kawarabayashi & Osa, 
1976).
However, at the last stage of gestation, activation of 
CX -adrenoceptors in the circular muscle cells is apparent 
(Osa & Watanabe, 1978). In the longitudinal muscle, 
activation of -adrenoceptors occurs during mid­
pregnancy and cx -adrenoceptors at term (Marshall, 1970).
Thus, a phenomenon akin to the "adrenaline reversal" in the 
cat occurs in the myometrium of various species (Dale, 
1906; Bulbring et al. 1968; Abe, 1970).
In non-pregnant rats Diamond and Brody (1966) found 
that an oestrogen treated muscle was excited by 
catecholamines (an CK -adrenoceptor effect), while a 
progesterone treated one was inhibited (a -adrenoceptor
effect). Similarly, Marshall (1967) showed that
noradrenaline relaxed uteri from ovariectomized rats 
treated with a combination of oestrogen and progesterone, 
but contracted those treated with oestrogen alone. Taken 
together, these findings suggest that oestrogen may 
increase the sensitivity of the -adrenoceptors to
catecholamines (Marshall, 1967, 1970). During the oestrous 
cycle, CK -adrenoceptors have been shown to be associated 
with the proestrus and oestrus phases (Butterworth & 
Randall, 197 0; Abdel-Aziz & Bakry, 197 3; Butterworth & 
Jarman, 1974; Boyle & Digges, 1982a; Boyle & Ohia, 1984; 
Acritopoulou-Foucroy et al. 1985), when the concentration
of circulating oestrogen is highest (Yoshinaga et al. 1969; 
Butcher et al, 1974; Brenner & West, 1975). Using the
radioligand binding method, Krall et al (1978) found that 
ex' -adrenoceptor density was increased in proestrus and 
oestrus, while -adrenoceptor density was raised only in
proestrus. These findings led Krall et al (1978) to 
suggest that changing receptor number might be one way 
through which the hormones regulated targets organ
function.
Recently, Morrison et al (1987) showed that there was 
no change in -adrenoceptor density (as measured by
I O C  , , ,
[ I]-lodocyanopinolol binding) in the rat uterus during 
the oestrous cycle. Thus there is good evidence that the 
ovarian hormones increase the CX, adrenoceptor
population, contributing to "the adrenaline reversal". The 
situation is less clear with the /Q> -adrenoceptors which 
do not appear to be altered by the ovarian hormones.
(ii) EFFECT OF AGONISTS REMOVAL MECHANISMS ON UTERINE
RESPONSE TO CATECHOLAMINES
The importance of amine removal mechanisms in 
terminating the physiological effects of catecholamines is 
well documented (Gillespie, 1973; Iversen, 1973). Uptake 
into neuronal (Uptake 2 ) and extraneuronal (Uptake 2) sites 
also have pharmacological relevance in that they can be 
modulated by drugs (O'Donnell & Wanstall, 1976; Kenakin, 
1983, 1984). Since steroids such as 17/6 -oestradiol and
progesterone have been shown to be potent inhibitors of the 
uptake2 process (Iversen & Salt, 1970; Salt, 1972) , 
attempts have been made to correlate ovarian hormonal level 
during the oestrous cycle with uterine sensitivity to 
catecholamines during the oestrous cycle (Digges & Boyle, 
1979; Boyle & Digges, 1982a,b). Boyle & Digges (1982a) 
found that the variations in the ovarian hormones in 
proestrus, oestrus, metoestrus and dioestrus were 
accompanied by differences in uterine uptake of the
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catecholamines. On the basis of these observations, Boyle 
& Digges (1982a) concluded that the extraneuronal uptake 
process was a major metabolic route for the disposal of 
catecholamines in the rat uterus and that this mechanism 
was in turn controlled by oestrogen and progesterone. 
Blockade of amine removal mechanism into neuronal and 
extraneuronal sites has also been shown to increase the 
maximum degree of inhibition produced by adrenoceptor 
agonists in the rat uterus in all phases of the oestrous 
cycle (Ohia, 1986). Although amine removal mechanisms 
appear to play an important role in the disposal of 
catecholamines in the rat uterus (Boyle & Digges, 1982a; 
Boyle & Ohia, 1984; Ohia, 1986), the possibility that this 
process could be regulated by the ovarian hormones is yet 
to be fully determined.
(C) INTRACELLULAR MECHANISMS INVOLVED IN UTERINE RESPONSE
TO CATECHOLAMINES
Uterine response to catecholamines is associated with 
changes in a number of intracellular processes such as 
ionic conductance and ion channel activity and cyclic 
nucleotide levels.
(i) ROLE OF ION CONDUCTANCE AND CHANNEL ACTIVITY
There is evidence that alterations in membrane 
permeability to both cations and anions by catecholamines 
could be one way through which they produce their effect in
the rat uterus (Goto & Csapo, 1959; Marshall, 1962, 1968).
Stimulation of -adrenoceptors in the circular muscle of 
the pregnant rat myometrium has been shown to cause 
depolarization accompanied by a decrease in membrane 
resistance which would suggest an increase in calcium 
and/or sodium conductance (Osa & Watanabe, 1978). In the 
guinea pig uterus, Bulbring and her co-workers (Szurszewski 
& Bulbring, 1973; Bulbring & Szurszewski, 1974; Bulbring, 
Ohashi & Tomita, 1981) demonstrated that depolarization 
caused by catecholamines was probably mainly due to an 
increase in chloride conductance because it was abolished 
by replacing chloride ions with glutamate, but not by 
replacing sodium with Tris. Thus, there may be species 
difference in the type of ionic changes induced by 
adrenoceptor activation in uterine smooth muscle.
Relaxation of rat myometrium due to stimulation of the 
-adrenoceptor is characterized by cessation of 
spontaneous action potential discharge, hyperpolarization 
of the membrane and relaxation of the muscle (Diamond & 
Marshall, 1969a,b; Kroeger & Marshall, 1973; Marshall & 
Kroeger, 1973). The hyperpolarization and reduction of the 
membrane resistance are not much affected by removal of 
external sodium or chloride ions (Marshall, 1968). 
However, the hyperpolarization appeared to be dependent on 
the potassium ion concentration in the extracellular fluid 
(Marshall, 1968, 1970). Marshall and Kroeger (1973) showed 
that catecholamine-induced hyperpolarization was dependent 
on the calcium concentration in the external medium and was
reduced by ouabain and low temperature (10°C). These 
findings led Marshall and her co-workers (Kroeger, Marshall 
& Bianchi, 1975; Marshall, 1977) to suggest that an 
outwardly directed calcium current could underlie the 
relaxation produced by catecholamines in the rat uterus. 
However there is evidence that hyperpolarization may not be 
a prerequisite for relaxation because Meisheri, McNeill and 
Marshall (1979) found that isoprenaline produced an 
inhibitory response in the pregnant rat myometrium without 
a change in membrane potential. On the whole, both uterine 
excitatory or inhibitory response to catecholamines appear 
to involve alterations in membrane permeability to ions 
which in most cases leads to a change in membrane 
potential.
(ii) ROLE OF CYCLIC NUCLEOTIDES
Adrenoceptors of the ^- and £  2 '"suktyPe are
positively coupled to adenylate cyclase, while activation 
of cx 2 "*ac^ renocePtors inhibits this enzyme (review by
Stiles, Caron & Lefkowitz, 1984). The relaxation caused by 
/? -adrenoceptor agonists is thought to involve an increase 
in adenosine 3',5f cyclic monophosphate (cAMP) formation 
following stimulation of adenylate cyclase, because:
(a) The relaxation is correlated with a concomitant
increase in tissue cAMP content (Dobbs & Robison, 1968;
Triner, Nahas, Vulliemoz, Overweg, Verosky, Habif & Ngai,
1971),
(b) cAMP (applied as the dibutyryl compound) mimicks the 
affect of -adrenoceptor ag onists (Mitznegg, Heim & 
Meythaler, 1970; Triner et al. 1971; Vesin & Harbon, 1974), 
and
(c) inhibitors of phosphodiesterase also have a relaxing 
effect (Triner et al. 1971).
In the rat uterus, cAMP appears to have satisfied the 
criteria for its role as a "second messenger" (Krall & 
Korenman, 1979; Kroeger, 1979; Kishikawa, 1981; Fortier & 
Krall, 1983). The mediatory role for cAMP has, however, 
been disputed by some workers (Polacek & Daniel, 1971; 
Harbon & Clauser, 1971; Diamond & Holmes, 1975; Meisheri & 
McNeill, 1979a,b; Marshall & Fain, 1985). Harbon and her 
co-workers found that adrenaline caused relaxation and 
increased rat uterine cAMP, both effects being antagonized 
by propranolol, but, in the same preparation, 
prostaglandins caused contraction and also increased cAMP 
which was not blocked by propranolol (Harbon & Clauser, 
1971; Vesin & Harbon, 1974) . It is possible that while 
cAMP can mediate relaxation in the rat uterus, under 
certain conditions, the nucleotide may not be an obligatory 
mediator.
An intermediary role for cAMP in the action of 
oestrogens in the rat uterus has been suggested by some 
workers (Marshall, 1973; Downing & Panter, 1980; Kishikawa, 
1981).
The molecular mechanism involved in cAMP-mediated 
effects has been determined biochemically. Fortier, Chase,
Korenman and Krall (1983) suggested that stimulation of 
adenylate cyclase may require the presence of guanyl- 
nucleotides, since isoprenaline-induced effects on the 
enzyme in cultured myometrial cells was dependent on the 
presence of GTP. Fortier et al (1983) also found that 
adenylate cyclase was activated directly by calcium without 
GTP indicating the existence of another, receptor- 
independent mechanism for cAMP production which may play a 
role in autoregulation of intracellular calcium in the rat 
myometrium. cAMP may also affect uterine calcium function 
by increasing calcium binding in the sarcoplasmic reticulum 
(Krall, Sorensen & Korenman, 1976). Phosphorylation of a 
specific protein in the microsome is likely to be 
responsible for cAMP-dependent accumulation in microsomes 
prepared from rat myometrium (Nishikori & Maeno, 1979). 
The effects produced by cAMP appear to be mediated by cAMP- 
dependent protein kinases (Dokhac, D'Albis, Janmot & 
Harbon, 1986; Bulbring & Tomita, 1987). In summary the 
molecular mechanisms involved in cAMP mediated effects 
following catecholamine induced activation is currently 
under investigation.
Although guanosine 3',5! cyclic monophosphate (cGMP) 
and its protein kinase have been demonstrated in the plasma 
membrane and cytoplasm of rat myometrial cells (Flandroy, 
Cheung & Steiner, 1983), there are few reports so far as to 
the possibility of an interaction between catecholamines 
and cGMP. However, the ovarian hormones have been shown to
affect cGMP levels in the rat uterus indicating a possible 
role for this nucleotide in the regulation of uterine 
motility (Flandroy & Galand, 1978, 1980; Kishikawa, 1981).
Kishikawa (1981) showed that at the early stage of 
pregnancy, cGMP levels were high in both longitudinal and 
circular muscles of the rat myometrium. cGMP levels, 
however, declined with the progress of pregnancy.
/ e
Phenyphrine had no effect on cGMP levels in the pregnant 
A
rat myometrium. Thus, it would appear that catecholamines 
do not interact with the processes leading to cGMP 
production in the rat uterus. The physiological 
significance of alterations in cGMP levels during pregnancy 
is unclear and merits further studies.
(D) INVOLVEMENT OF PROSTAGLANDINS IN THE EXCITATORY AND
INHIBITORY EFFECTS OF CATECHOLAMINES
Prostaglandins have been shown to play an important 
role in the physiological control of uterine function and 
in parturition (as reviewed by Harbon & Poyser, 1976; Novy 
& Liggins, 1980). In pregnant rats, Vane and Williams 
(1973) showed that uterine prostaglandin release from 
isolated preparations increased until it reached a maximum 
on the expected day of delivery. Post-partum, a decrease 
in uterine prostaglandin release was observed by Harney, 
Sneddon and Williams (1974). During the oestrous cycle, 
uteri from the four phases can generate prostaglandins of 
the E and F series (Poyser & Scott, 198 0; Van Orden, 
Goodale, Baker, Barley & Chatnagar, 1980; Franchi, Chand,
Borda, Gimeno, Lazzari & Gimeno, 1981; Gimeno & Gimeno, 
1984; Brown & Poyser, 1985). In the rat uterus, while both 
the myometrium and endometrium can synthesize 
prostaglandins, the endometrium appears to be the major 
source (Campos, Liggins & Seamark, 1980; Brown & Poyser, 
1985).
Uterine prostaglandin production has been shown to be 
under the influence of the ovarian hormones (Castracane & 
Jordan, 1975; Carinmate, Lazzani, Soffientini & Larner, 
1975; Kogo, Yamada & Aizawa, 1977; Sterin-Speziale, Gimeno, 
Bonacossa & Gimeno, 1980). Oestrogen appears to be the 
main ovarian steroid involved in the regulation of uterine 
prostaglandin synthesis, but a prior period of exposure to 
progesterone may be necessary (Castracane & Jordan, 1976; 
Gimeno & Gimeno, 1984). Both uterine prostaglandin E and F 
(Sharma & Garg, 1977; Wilson, 1983) or prostaglandin F 
alone (Ham, Girillo, Zanetti & Kuehl, 1975; Sterin-Speziale 
et al. 1980) have been demonstrated to be regulated by
oestrogen. Ovarian hormonal effects on uterine
prostaglandin production may play a role in implantation 
and decidualization in the rat (Malathy, Cheng & Dey, 1986; 
Tawfik, Huet, Malathy, Johnson & Dey, 1987).
There is evidence that prostaglandins may modulate 
both neurotransmitter release from adrenergic neurons and 
the responsiveness of the post-synaptic cell to 
noradrenaline (Hedqvist, 1977; Malik, 1978). 
Prostaglandins of the E series inhibit the release of
34
noradrenaline from sympathetic nerves, while inhibition of 
prostaglandin synthesis results in an increase in 
noradrenaline release (Samuelsson & Wennhalm, 1971). In 
the rat uterus, very low concentrations of prostaglandins 
have been shown to antagonize catecholamine-induced 
inhibitory responses (Clegg, 1966). A similar interaction 
between prostaglandins and catecholamines has also been 
reported by other workers (Vesin & Harbon, 1974; Krall, 
Banett, Jamgotchian & Korenman, 1984). However,
catecholamines have been shown to stimulate prostaglandin 
biosynthesis and release from various tissues including the 
spleen (Gilmore, Vane & Wyllie, 1968; Bedwani & Millar, 
1975; Bruckner-Schmidt, Jackish & Hertting, 1981), seminal 
vesicles (Egan, Humes & Kuehl, 1978), kidney (Davis &
Harton, 1972; Needleman, Douglas, Staecklein & Johnson,
1974), cultured cells (Levine & Moskowitz, 1979), brain 
(Hillier & Templeton, 1982; Yohai & Danon, 1987), iris- 
ciliary body (Yohai & Danon, 1987), vas deferens (Trachte, 
1987) and heart (Wennhalm & Brundin, 1978; Weis & Malik, 
1985, 1986; Molderings & Schumann, 1987).
Stimulation of uterine prostaglandin biosynthesis by 
adrenoceptor agonists has been demonstrated in humans 
(Quaas & Zahradnik, 1985; Wikland, Lindblom & Wigvist, 
1985; Quaas, Goppinger & Zahradnik, 1987), sheep (Lye, 
Christopher & Casper, 1987), guinea-pigs (Takei & Moritoki,
1987) and rats (Boyle & Ohia, 1985a,b; Chaud, Franchi, 
Gonzalez, Gimeno & Gimeno, 1986; Ohia, 1986; Ohia & Boyle,
1988) .
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The mechanism involved in catecholamine-induced 
prostaglandin biosynthesis is not well understood. 
Evidence from biochemical studies reveal that 
catecholamines can directly stimulate cyclo-oxygenase 
activity (Egan et al. 1978 , Banmann, Von Bruchhausen &
Wurm, 1979). Activation of prostaglandin synthesis by 
catecholamines appears to be associated with an effect on 
adrenoceptors of the CK -(Ojeda, Negro-Vilar & McCann, 
1982; Ritta & Cardinali, 1982; Borda, Peredo & Gimeno, 
1983; Molderings & Schumann, 1987), ji -(Dusling & Nolan, 
1981; Qmini, Folco, Sautebin, Nara, Mandelli & Feruccio, 
1981; Shaffer & Malik, 1982; Lye et al 1987) and - and 
J& -subtypes (Boyle & Ohia, 1985a,b; Ohia, 1986; Chand et 
al, 1986; Trachte, 1987). In general, the prostaglandins 
generated by catecholamines produced excitatory effects 
which have been ascribed to either a direct action of 
prostaglandins on intracellular calcium binding sites 
leading to a decrease in calcium storage (Carsten, 1974; 
Reiner & Marshall, 1976; Carsten & Miller, 1977) or an 
inhibition of plasma membrane Ca2+/Mg2+-ATPase resulting in 
an overall inhibition of calcium efflux (Deliconstantinos & 
Fotiou, 1986).
Uterine response to catecholamines appears to be under 
the influence of several factors which could affect the 
types of adrenoceptors present (e.g. ovarian hormones), 
potency at receptor sites (e.g. agonists removal 
mechanisms) and the intracellular processes involved in its 
action (e.g. prostaglandins). As discussed above, some of
these factors may interact with each other and at different 
levels of the catecholamine induced response.
The aim of the present study was three-fold (i) to 
further investigate the mechanism responsible for the 
variation in uterine response to adrenoceptor agonists in 
the four phases of the oestrous cycle, (ii) to examine the 
possible involvement of prostaglandins in adrenoceptor 
agonists effects in uteri from non-pregnant, pregnant and 
post-partum animals in order to fully assess the role of 
prostaglandins in the observed variation in response, and
(iii) to determine if changes in tissue cAMP metabolism 
could play a role in the altered uterine response to 
adrenoceptor agonists in non-pregnant and pregnant rats.
CHAPTER 2 
MATERIALS AND METHODS
A. ANIMALS
Female Wistar strain rats were used in all 
experiments. There were four groups of animals:-
i) Virgin rats in the weight range 180-220 g. 
ii) Oestrogen pretreated virgin rats in the weight 
range 180-220 g. 
iii) 20-day pregnant rats in the weight range 200-280 g 
iv) 1-day post-partum rats in the weight range 200-280
B. VIRGIN RATS - VAGINAL SMEARS
In rats, cyclical production of ovarian hormones 
results in an oestrous cycle which lasts 4 to 5 days, and 
can be divided into four phases - prooestrus, oestrus, 
metoestrus, and dioestrus. While the primary events take 
place in the ovaries and uterus, changes also occur in the 
vagina which undergoes cyclical disintegration, the debris 
accumulates thereafter in the lumen and can be used to 
identify the four phases of the cycle. The events 
occurring in the ovaries, and the vaginal histology of rats 
in proestrus, oestrus, metoestrus, and dioestrus are 
summarized as shown in Table I. Vaginal smears were taken 
immediately after the animals were killed. 0.5 ml of 
distilled water was inserted into the vagina from a Pasteur 
pipette. The fluid containing shed vaginal cells was then 
withdrawn, placed on a glass slide, and air dried. The 
smears were stained with 0.1% (w/v) Methylene blue and
examined under a microscope. Vaginal smears from each 
phase of the oestrus cycle are shown in Plate I.
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TABLE 1:
Ovarian events, gross appearance of uterus and vaginal histology of 
rats during the oestrous cycle.
Phase
Duration 
of phase
Ovarian
events
Gross 
Appearance 
of uterus
Smear
Appearance
Proestrus 12 hours Follicles grov 
fast and 
approach sur­
face of ovary
Uterus
swollen with 
secretion. 
Blood vessels 
engorged.
Nucleated 
epithelial 
cells only
Oestrus 12-18 hours Ovulation
occurs
Uterus remains 
swollen 
blood vessels 
still 
engorged
Comified 
squamous 
cells only
Metoestrus 10-14 hours Corpora lutea 
formed
Uterus
becomes
smaller
Comified
cells,
nucleated
epithelial
cells and
polymorpho-
nucleated
leucocytes
Dioestrus 48-60 hours Regression of 
corpora lutea.
Uterus 
becomes 
smaller 
and thin
Nucleated 
epithelial 
cells and 
leucocytes
Plate I Vaginal Smears:
A. Proestrus
B. Oestrus
C. Metoestrus
D. Dioestrus
Nucleated epithelial cells only.
Cornified squamous cells only.
Cornified cells, nucleated epithelial 
cells and polymorphonucleated 
leucocyte
Nucleated epithelial cells and 
leucocytes.
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Since there is evidence that ovariectomy enhances 
uterine inhibitory responses to catecholamines, suggesting 
a role for the ovarian hormones in the observed variation 
in their action during the oestrous cycle, it was decided 
to investigate the role of ovarian hormones using a 
different model. Animals were pretreated with oestradiol 
in order to induce oestrus. The steroid was dissolved in 
corn oil, and 0.2 mg/kg administered by intraperitoneal 
injection 24 hours prior to sacrifice. The effectiveness 
of this treatment in inducing oestrus, was verified by 
microscopic examination of vaginal smears.
C. PREGNANT AND POST-PARTUM RATS
i) 20 day pregnant rats: Females were placed in cages with 
males in a ratio of 1:1. The appearance of a vaginal plug 
was taken as day one of pregnancy. The gestation period in 
the rat is of approximately 21 days duration and animals 
were sacrificed at 20 days into gestation, i.e. prior to 
parturition.
ii) 1 day post-partum rats: Rats were mated as described 
for the 20 day pregnant animals. Uteri were taken from 
animals on the first day following parturition.
D. ISOLATED UTERINE HORN PREPARATIONS
i) Virgin rats
All animals were killed by stunning and 
exsanguination. The uterus was exposed after a mid line
abdominal incision and isolated from the surrounding 
mesentery.
Two to three cm lengths from the mid portion of each 
uterine horn were used. The tissues were mounted in paired 
10 ml organ baths containing tyrode solution, (see Table 2) 
at 37°C and aerated with 95% 02 5% C02 mixture. Isometric 
tension was recorded via Grass displacement transducers. An 
initial tension of 0.5 g was applied to each horn, and the 
tissues were left to equilibrate for at least 1 hour. 
Uteri from animals in the metoestrus and dioestrus phases 
usually exhibited spontaneous activity on first being 
mounted. However, the spontaneous activity disappeared 
after exposure of the tissues to acetylcholine (AcH).
ii) 20 Day pregnant rats and 1 day post-partum rats
The uteri from 20 day pregnant and 1 day post-partum 
rats were cut open along the mesenteric border and the 
foetuses expelled in the pregnant animal. Longitudinal 
strips were prepared (2-3 cm in length) and set up for 
isometric recording, in the same way as with the horn 
preparations from the non-pregnant rats. In a series of 
experiments, the endometrial layer was removed by gently 
scraping the inner surface of the opened uterus under a 
dissecting microscope, a longitudinal strip of the 
remaining myometrium was then set up for isometric 
recording. One strip was prepared from each uterine horn. 
Uteri from 20 day pregnant animals exhibited spontaneous 
activity on mounting. The spontaneous activity disappeared 
after exposure of the tissues to Ach.
TABLE 2:
Composition of Tyrode solution.
Compound Concentration (mmol/1)
NaCl 136.90
KC1 2.68
CaCl2.6H20 1.80
MgCl2.6H20 1.05
NaHC03 11.90
NaH2.P042H20 0.42
Glucose 5.55
E. MOTOR RESPONSES TO ACETYLCHOLINE
Since the rat uterus does not possess intrinsic tone,
it was necessary to induce tone in order to measure the
relaxation produced by drugs.
In the present study, acetylcholine was used to induce 
tone in uteri from the four phases of the oestrous cycle, 
during pregnancy, and post-partum.
Concentration-response curves were constructed to Ach 
in each preparation. Doses of Ach were added every four 
minutes, and allowed to act for 30 seconds before being 
washed out. The dose that produced approximately 60-70% of 
the maximum response to Ach was chosen as a standard which 
was used throughout the remainder of the experiment.
The response to the standard dose of Ach at the end of 
each experiment was not significantly different from that 
at the start of the experiment.
F. EXPERIMENTS ON UTERI FROM NON-PREGNANT RATS
i) Experiments on uteri in the four stages of the oestrous
cycle
1) Inhibitory responses to adrenoceptor agonists
In all experiments, the inhibitory responses to the 
adrenoceptor agonists, noradrenaline (NA), adrenaline 
(ADR), salbutamol (SAL) and isoxsuprine (ISOX) were 
examined in uteri in which tone was induced with Ach as 
described earlier. In each experiment, only one 
adrenoceptor agonist was used.
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The adrenoceptor agonists were added to the organ bath 
3 0 seconds before the standard dose of Ach. The inhibitory 
effect of the adrenoceptor agonists was determined as 
percentage reduction of Ach motor response.
Preliminary experiments had shown that the inhibitory 
effects of the adrenoceptor agonists were fully developed 
within 30 seconds. After inhibition with the agonists, the 
standard Ach response was allowed to recover fully before 
addition of the next dose of agonist.
Experiments in which only the adrenoceptor agonists 
were present are referred to as Control I studies.
In all subsequent experiments, control responses to 
Ach and the adrenoceptor agonist under investigation were 
obtained, before the addition of any antagonists.
2) Inhibitory response to adrenoceptor agonists in the 
presence of an 4X adrenoceptor antagonist
The existence in the uterus of 0( -excitatory
receptors in addition to the well characterized 
inhibitory receptors, could influence the response to 
adrenoceptor agonists active at both receptors. The 
observed response to such agonists would then be the 
algebraic sum of contraction plus relaxation.
In a series of experiments, (X -receptor activity was 
abolished by using the alpha receptor antagonist Azapetine 
(AZA) . AZA (10“ 6  M) was added to the reservoir of tyrode
solution, and was present throughout the remainder of the 
experiment. Tissues were exposed to AZA for at least 30
minutes before addition of Ach and the adrenoceptor 
agonists.
3) Inhibitory responses to adrenoceptor agonists in the 
presence of inhibitors of neuronal and extraneuronal uptake
Agonist concentration at the receptor could be 
affected by amine removal mechanisms, i.e. uptake into 
neuronal (uptake I) and non-neuronal (uptake 2) tissues.
The contribution of the uptake processes to 
adrenoceptor agonists inhibitory responses was studied by 
using desmethylimipramine (DMI) to block uptake I and 
normetanephrine (NMN) to block uptake 2. When used both 
DMI (10“ 6  M) and NMN (10- 6  M) were added to the reservoir 
and were present in the tyrode solution throughout the 
remainder of the experiment. Tissues were exposed to DMI 
and NMN for at least 30 minutes before addition of Ach and 
the adrenoceptor agonists.
4) Inhibitory response to adrenoceptor agonists in the 
presence of an OK -receptor antagonist and inhibitors 
of neuronal and extraneuronal uptake
Since both (X -excitatory receptors and amine removal 
mechanisms affected adrenoceptor agonist responses, a
series of experiments was performed in which all three 
drugs AZA (10- 6  M) , DMI (10- 6  M) and NMN (10~ 6  M) were 
present. As before the antagonists were added to the 
tyrodes reservoir and were present throughout the remainder
of the experiment. Such experiments are referred to as 
Control II studies.
5) Inhibitory— responses to adrenoceptor agonists in the 
presence of a— cyclo-oxyqenase inhibitor flurbiprofen
Intramurally generated prostaglandins produce 
excitatory effects on uterine motility. The possibility 
that prostaglandins may influence the inhibitory responses 
of adrenoceptor agonists was investigated in two series of 
experiments in which their biosynthesis was prevented by 
inhibiting cyclo-oxygenase with flurbiprofen (FBF). In the 
first series, the controls were of the control I type i.e. 
agonists alone, (see Section Fi.l) while in the second 
series, controls were of the Control II type i.e. all the 
three antagonists were present (see Section Fi.4).
The adrenoceptor agonist used was SAL because of its 
selectivity for /-* -adrenoceptors. After obtaining control 
responses, FBF (10“ 5  M) was added to the tyrodes reservoir 
and was present in the tyrode solution for the remainder of 
these experiments. Tissues were exposed to (FBF) for at 
least 1  hour before addition of the adrenoceptor agonists.
ii) Experiments on uteri from oestrogen pretreated rats
1) Inhibitory responses to salbutamol, isoprenaline and 
isoxSnprine
The inhibitory responses to the adrenoceptor agonists 
Salbutamol (SAL), Isoprenaline (ISO), and Isosuxprine 
(ISOX) were studied in uteri exposed to oestrogen in which
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tone was induced with Ach as in those from animals during 
the natural oestrous cycle. Control I studies were 
performed for SAL, ISO, and ISOX and no antagonists were 
present.
2) Inhibitory responses to adrenoceptor agonists in
presence of (FBF)
The possibility that intramural prostaglandin 
production may influence adrenoceptor agonist inhibitory 
responses in uteri from animals pre-treated with oestrogen 
was investigated. The effects of SAL, ISO and ISOX were 
examined in the presence of (FBF) as described in Section 
Fi.5.
3) Inhibitory responses to adrenoceptor agonists in the 
presence of a phospholipase An inhibitor, Ouinacrine
The concentration of free-fatty acids within cells is 
low and thus the initial and rate limiting step in the 
biosynthesis of prostaglandins is the enzymic liberation of 
free arachidonic acid from ester pools. Arachidonic acid 
is located predominantly in the 2 -position of phospholipids 
and its release occurs by hydrolysis controlled by 
phospholipase A2 •
Thus in order to further examine the role of 
intramurally generated prostaglandins in uterine response 
to adrenoceptor agonists, a series of experiments was 
performed in the presence of the phospholipase A 2
inhibitor quinacrine. Control I studies were performed for 
SAL and quinacrine (10~^ M) was present in the tyrode
solution for the remainder of these experiments.
Tissues were exposed to quinacrine for at least 45 
minutes before the addition of SAL.
4) Inhibitory responses to adrenoceptor agonists in the 
presence of a cvclo-oxygenase inhibitor (FBF) and 
arachidonic acid 
A series of experiments was carried out to determine 
if the effects elicited by the cyclo-oxygenase inhibitor, 
FBF, can be reversed in the presence of exogenous 
arachidonic acid. FBF was present in the tyrodes solution 
from the start of the experiment, and concentration curves 
for SAL were obtained. Arachidonic acid (10- 6  m) was then 
added to the tyrode's reservoir and was present for the 
remainder of the experiment.
Tissues were exposed to FBF and arachidonic acid for
at least 1  hour before the addition of SAL.
G) EXPERIMENTS ON UTERI FROM 20 DAY PREGNANT AND ONE-DAY 
POST-PARTUM RATS 
Two series of experiments were performed to 
investigate the role of prostaglandins in uterine response 
to adrenoceptor agonists in late pregnancy and early post­
partum. In the first series, adrenoceptor agonist effects 
were examined in uteri with the endometrium present while 
in the second series, endometrium-free preparations were
employed.
The effects of the cyclo-oxygenase inhibitor, FBF, 
were examined in each of the series.
i) Experiments on uterine preparations with endometrium 
present
Inhibitory responses to adrenoceptor agonists in pregnant 
uteri in the presence of a cyclo-oxygenase inhibitor.
The role of the prostaglandins in adrenoceptor 
induced inhibition in pregnant and post-partum rats was 
investigated by examining the effects of F1F on the 
responses to ADR and SAL. After obtaining control 
responses to ADR and SAL, FBF (10" 5  M) was added to the 
tyrode solution for the remainder of these experiments. 
Tissues were exposed to FBF for at least 1 hour before the 
addition of the adrenoceptor agonists.
ii) Experiments on uterine preparations with endometrium 
removed
Inhibitory responses to adrenoceptor agonists in pregnant 
and post-partum myometrium in the presence of a cycle- 
oxvaenase Inhibitor
As with experiments on pregnant and post-partum uteri 
with intact endometrium (Section G(i)), both Control I and 
Control II studies were carried out for ADR and SAL before 
and after the addition of FBF (10“® M) »
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H) Measurement of adenosine 3*5' cyclic monophosphate 
content in the uterus 
Stimulation of -adrenoceptors in the rat uterus as
in other tissues increases tissue adenosine 3'5' cyclic 
monophosphate (cAMP) content. The effect of the 
receptor agonist, SAL, on cAMP levels, was investigated in 
the four phases of the oestrous cycle.
i) Extraction of tissue cAMP
Animals were killed, and the phase of the oestrous 
cycle identified from vaginal smears. The uterus was 
isolated and 1 cm lengths of each horn were blotted dry and 
weighed. Tissues were incubated in Tyrodes solution 
containing a phosphodiesterase inhibitor, theophylline 
(10- 3  M) at 37°C for 1 hour. After incubation, the tissues 
were blotted dry and quickly transferred to small tubes 
containing 1 ml of ice-cold 5% trichloroacetic acid (TCA), 
which were left in a cold room (2-4°C) for 24 hours.
0.5 ml of the TCA extract was transferred from each 
sample tube to a correspondingly marked tube, and 2 ml of 
water saturated diethyl ether were added and vortexed for 5 
seconds. The ether phase was removed using a Pasteur 
pipette and discarded. The process of adding ether, 
vortexing and removing the ether layer was repeated twice. 
Any remaining ether was evaporated off in a water bath at 
80°C. Some crystals of calcium carbonate were added to 
each tube to neutralize any remaining TCA and to maintain a 
constant sample pH.
ii) Assay of cAMP
The cAMP assay was performed using a radioimmunoassay 
kit purchased from Amersham International PLC. The assay 
is based on competition between unlabelled cAMP and a fixed 
quantity of Tritium Labelled compound for binding to a 
protein which has a high affinity and specificity for cAMP. 
Measurement of protein-bound radioactivity enables the 
amount of unlabelled c A M P  in the sample to be calcu la te d.
The amount of la b e l l e d  p r o t e i n - c A M P  c o m p l e x  formed is 
related inversely to the a m o u n t  of u n l a b e l l e d  c A M P  p r e s e n t  
in the assay sample.
Separation of the p r o t e i n  b o u n d  c A M P  from u n b o u n d  
nucleotide is achieved by adsorption of the free nucleotide 
on to coated charcoal, followed by centrifugation. A n  
aliquot of the supernatant containing the bound n u c l e o t i d e  
is then removed for liquid scintillation counting. The 
concentration of unlabelled c A M P  is then determined from a 
linear standard curve.
1) Preparation of s t a n d a r d  c A M P  s o l u t i o n
0 . 5  ml Tris E D T A  b u f f e r  (50 m M  T r i s / H C l  s o l u t i o n  
containing 4 mM EDTA at pH 7.5) was a d d e d  t o  e a c h  of four 
small glass t u b e s .  0.5  ml o f  a d e n o s i n e  3 ' 5 f c y c l i c  
phosphate standard (32 0 pmol) w a s  a dd ed  to t h e  f irst tube 
and mixed. 0.5 ml of t hi s  d i l u t i o n  w a s  t r a n s f e r r e d  to the 
second tube and mixed again, w i t h  e a c h  r e m a i n i n g  tube. 
Together with the original solution, five c o n c e n t r a t i o n s  of 
standard c A M P  were prepared. 50/^1 from e a c h  s o l u t i o n  g ave
16, 8 , 4, 2 and 1 pmol and were used for preparation of the
calibration curve.
2) Assay procedure
(1) Fourteen assay tubes for standards, and additional 
tubes for unknowns in duplicate, were maintained 
at 0°C in an ice bath. The tubes were labelled 
consecutively.
(2) 150 /J 1 of Tris EDTA were pipetted into tubes 1 
and 2 , which were used for the determination of 
blank counts per minute.
(3) 50 // 1 of Tris EDTA buffer were pipetted into
tubes 3 and 4, for determination of binding in the 
absence of unlabelled cAMP.
(4) Beginning with the lowest concentration of 
standard cAMP, 50 (J1 of each dilution were added 
into each successive pair of assay tubes (5-14).
(5) 50 M 1 of each unknown sample, in duplicate, were 
added into the remaining assay tubes as required.
(6 ) 50 Jj 1 of the labelled compound [8 - H] adenosine 
3'5’ cyclic phosphate (5 ^ /Ci) were added to each 
assay tube.
(7 ) 1 0 0  // 1  of the binding protein, purified from
bovine muscle, were added to all tubes with the 
exception of the blanks.
(8 ) All tubes were vortexed for 5 seconds.
(9) The tubes, contained in the ice bath, were left in 
the cold room (2-4°C) for 2 hours.
(10) Fifteen minutes before the end of incubation time, 
20 ml of ice-cold distilled water were added to 
the charcoal reagent in a beaker, which was placed 
in an ice bath and stirred continuously with a 
magnetic stirrer.
(11) 100 //I of the charcoal suspension were added to 
all assay tubes and vortexed for 5 seconds. 
Charcoal was added only to the number of tubes 
which could be centrifuged in one batch.
(12) The tubes were centrifuged at 12,000g for 5
minutes in a refrigerated centrifuge to sediment 
the charcoal.
(13) Without disturbing the sediment a 200 jbt 1 sample 
from each tube were removed and placed in vials 
containing 1 0  ml of scintillant Es 299.
(14) Samples were counted for radioactivity in a PACKARD
Tri-CARB liquid scintillation analyzer (Model 2000 
CA) .
3) Preparation of standard curve_fQ£_cAMP assay
(1) The blank counts per minute (epm) for the assay
were determined from the mean epm for tubes 1 and 
2.
(2) The epm bound in the absence of unlabelled cAMP
(Co) were obtained from the mean epm for tubes 3 
and 4 , and then subtracted from the blank epm.
(3) The epm bound in the presence of unlabelled cAMP 
(Cx) were determined by first averaging the epm 
for each pair of duplicates in tubes 5-14 for the 
standard, and the additional pairs of tubes for 
the unknown. The results were then subtracted 
from the blank epm to give Cx.
(4) Co/Cx was calculated for e ac h  c o n c e n t r a t i o n  of  
standard cAMP and t h e  u nknowns.
(5) Co/Cx was plotted a g a i n s t  p m o l e s  o f  s t a n d a r d  
cAMP/tube to give t h e  s t a n d a r d  c u r v e  as s h o w n  in 
Figure I. A s t r a i g h t  line was  o b t a i n e d  w i t h  an 
intercept of 1 . 0  on t he  ordinate.
(6 ) From the Co/Cx value for the u nk nowns, the  n u m b e r  
of pmoles of c A M P  was r e a d  from the s t a n d a r d  
curve. The c A M P  c o n c e n t r a t i o n  was  e x p r e s s e d  as 
pmol/g wet weight of tissue.
iii) Measurement of t i s s u e  c A M P  in the f our p h a s e s o f  the 
oestrous cycle.
1) Measurement of basal tissue cAMP
Since variation in the ovarian hormones may affect 
cAMP generation, basal cAMP levels were measured in uteri 
from rats in proestrus, oestrus, metoestrus and dioestrus 
phases.
cAMP standard curve
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Concentration of cAMP (pmol/incubation tube)
Fig 1 ; STANDARD CURVE FOR determination of unknown cAMP concentration 
in samples. Co = counts per minute (c.p.m.) of labelled 
compound bound in the absence of unlabelled cAMP:Cx = c.p.m. 
of labelled compound bound in the presence of standard 
unlabelled cAMP.
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2) Measurement of the effect of a ^  -adrenoceptor agonist 
on cAMP levels
The effect of the -receptor agonist SAL on cAMP
levels was investigated in a series of experiments. The 
SAL concentration used was in the range 10“9M to 10~5 M ) .
Tissues were incubated in Tyrode solution at 37°C for 
1 hour. After incubation, tissues were transferred to 
Tyrode solution containing various concentrations of SAL 
for 1 minute, and then immediately subjected to cAMP 
analysis.
3) Measurement of the effect of a cvclo-oxvgenase inhibitor 
on cAMP levels
In a series of experiments, the effect of 
intramurally generated prostaglandins on cAMP levels was 
examined in uteri from the four phases of the oestrous 
cycle. Tissues were incubated in Tyrode solution 
containing the cyclo-oxygenase inhibitor FBF (10“ 5 M) at 
37°C for 1 hour, and then immediately subjected to cAMP 
analysis.
4) Measurement of the effect of a ^  -adrenoceptor agonist 
on cAMP levels in the presence of a cyclo-oxygenase 
inhibitor
The effect of SAL (10~9M - 10“5 M) on cAMP levels was 
determined in uteri from the four phases of the oestrous
cycle, after treatment with the cyclo-oxygenase inhibitor, 
FBF. Tissues were incubated in Tyrode solution containing
FBF (10 5 M) at 37°C for 1 hour. After incubation, the 
tissues were transferred to Tyrode solution containing FBF 
and SAL for 1 minute, and then immediately subjected to 
cAMP analysis.
iv) Measurement of tissue cAMP in uteri from 20-dav 
pregnant rats
1. Measurement of basal tissue cAMP levels
Basal tissue cAMP was measured in uterine preparations 
from 2 0-day pregnant animals. Two series of experiments 
were carried out. In the first, the uterus was intact,
1.e. the endometrium was present, while in the second, the 
endometrium was removed (as described in Section D.ii).
A2. Measurement of the effect of a ^  -adrenoceptor agonist 
on basal cAMP levels
The effect of SAL (10-9M - 10“5 M) on cAMP levels was 
investigated in uteri with endometrium present and in uteri 
from which the endometrium was removed. Tissues were 
exposed to SAL for 1 minute as described in Section H.iii,
2 and then immediately subjected to cAMP analysis.
CHEMICALS AND DRUGS
Acetylcholine
Arachidonic acid
DL-Adrenaline bitartrate
Ascorbic acid
Azapetine phosphate
Desmethylimipramine hydro­
chloride
Glucose
Isprenaline hydrochloride
Isoxsuprine hydrochloride
Magnesium chloride
Methylene blue
L-Noradrenaline bitartrate
DL-Normetanephrine hydro­
chloride
Ofestnidiol i 7  B
Potassiuia chloride
Quinacrine dihydrochloride
Salbutamol sulphate
Scintillant ES 299
Sodium bicarbonate
Sodium chloride
Sodium dihydrogen ortho­
phosphate
Sodium flurbiprofen dihydrate 
Theophylline
Sigma
Sigma
Sigma
B.D.H.
Roche
Geigy
Formachem
Amersham
Sigma
M & B
B,D.H.
Sigma
Sigma
Koch-Light
Sigma
Glaxo
Amersham
Koch-Light
Koch-Light
Arnalar
Boots
Sigma
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J. STATISTICS
All values given are mean + standard error of the 
mean. Student's t-tests were carried out to compare 
results. In diagrams and tables * represents p < 0.05; ** 
represents p < 0 .0 1 ? and *** represents p < 0 .0 0 1 .
EC 5 0  values were derived from individual concentration 
response curves. pD2 values = negative log 1 0  EC5Q.
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(1) ISOLATED UTERINE HORN PREPARATIONS
(A) RESPONSES TO ACETYLCHOLINE
Acetylcholine (Ach) in the concentration range (10“®M 
to 3 x 10 4  M) produced a concentration-related contraction 
of the non-pregnant, pregnant and post-partum rat uteri.
The mean maximum tension developed to Ach under these 
conditions varied significantly (Table 3) . Within the 
oestrous cycle, the highest, maximum tension was achieved 
in oestrus and the lowest in dioestrus while in pregnant 
and post-partum animals a considerably higher tension was 
developed when compared to non-pregnant preparations. 
These differences were significant at P < 0.001. No
variation in potency as estimated from values to Ach
was observed in uteri from non-pregnant, pregnant and post­
partum rats (Table 3).
Since the tension induced by Ach varied, a 
concentration-response curve was required in each 
experiment and the dose which produced approximately 60-7 0% 
of the maximum was then used as the standard, for the 
remainder of the experiment. Thus, agonist inhibitory 
effects could be measured as a reduction of this standard 
Ach response. The response to the standard dose of Ach at 
the end of each experiment was not significantly different 
from that at the beginning.
(B) RESPONSES TO ADRENOCEPTOR AGONISTS IN THE FOUR PHASES
OF THE OESTROUS CYCLE
The criteria used for the choice of the agonists were
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Table 3:
Maximum tension developed to Acetylcholine (Ach) and potency in 
nonpregnant, pregnant and post partum rat uteri.
Hormonal state Maximum tension Potency (pD2 values) (n)
of animal 0
Proestrus 4.09 ± 0.56 7.86 ±0.13 (16)
Oestrus 4.90 ± 0.57 8.29 ± 0.20 (14)
Metoestrus 3.63 ± 0.66 8.05 ±0.21 (14)
Dioestrus 3.58 ±0.80 8.20 ±0.31 (14)
20-day pregnant 12.00 ± 0.35 7.91 ±0.31 (6)
Post partum 9.83 ± 0.30 7.72 ± 0.39 (6)
Values are mean ± S.E.M., n = number of observations.
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based on their physiological and pharmacological 
importance. The endogenous catecholamines noradrenaline 
(NA) and adrenaline (ADR) are the adrenergic 
neurotransmitter and the adrenal hormone respectively, and 
both activate - and -adrenoceptors*.
. The non-catecholamine salbutamol (SAL) is, 
however, selective for -adrenoceptors of the 2-
subtype.
(a) Noradrenaline
Concentration response curves and pD 2 values for NA in 
proestrus, oestrus, metoestrus and dioestrus are shown in
_ Q
Figures 2 to 5 and Table 4, respectively. NA (10 M - 
10” 5  M) produced concentration-related inhibition of the 
standard Ach-induced contraction in the four phases of the 
oestrus cycle. The maximum degrees of inhibition produced 
during the cycle were approximately: proestrus, 35%;
oestrus, 30%; metoestrus, 40% and dioestrus, 30%. Uteri 
from the oestrus phase were most sensitive to the 
inhibitory effects of NA (Table 4).
(b) Adrenaline
Concentration-response curves and pD2 values for ADR 
in proestrus, oestrus, metoestrus and dioestrus are shown 
in Figures 6  to 9 and Table 5, respectively. ADR (3 x 
10” 1 0  M - 10 - 6  M) elicited concentration dependent 
inhibition of the standard Ach-induced contraction in all 
phases of the oestrus cycle. The maximum degrees of 
inhibition produced during the cycle were approximately:
in
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FIGURE 2; Log. concentration response curves to noradrenaline, 
in the rat isolated uterus in proestrus: Controls; in presence 
of azapetine (AZA, 10 ° M); in presence of desipramine 
(DMI, 10 ° M) and normetanephrine (NMN. 10“®); in presence 
of AZA with DMI and NMN (all at 10“° M). Number of 
observations in brackets.
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NA oestrus
80 n
• Control 
• -- • AZA
o — o  DMI + N 
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FIGURE 3: Log. concentration response curves to noradrenaline,
in the rat isolated uterus in oestrus: Controls; in presence
of azapetine (AZA, 1CT6 M); in presence of desipramine (DMI, 10"b M) 
and normetanephrine (NMN, 10”6 M); in presence of AZA with DMI 
and NMN (all at 10“° M). Number of observations in brackets.
NA metoestrus
100-1 • Control 
•— • AZA 
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□ — □ DMI + NMN + AZA
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FIGURE 4: Log. concentration response curves to noradrenaline, 
in the rat isolated uterus in metoestrus; Controls; in 
presence of azapetine (AZA, 10 M); in presence of
desipramine (DMI, 10 M) and normetanephrine (NMN. 10“^ M); 
in presence of AZA with DMI and NMN (all at 10”° M).
Number of observations in brackets.
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FIGURE 5: Log. concentration response curves to noradrenaline, 
in the rat isolated uterus in dioestrus: Controls; in
presence of azapetine (AZA, 10“6 M); in presence of 
desipramine (DMI, 10 M) and normetanephrine (NMN, 10"^ M); 
in presence of AZA with DMI and NMN (all at 10“6 m). Number 
of observations in brackets.
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Table 4:
Noradrenaline potency in uteri from the four p h a ses  
of the oestrous cycle (pD2 values).
Phase Potency (pD2) (n)
Proestrus 6.92 ± 0 .51 (7)
O estrus 7.40 ± 0 .0 9 (16)
M etoestrus 6.70 ± 0 .0 8 (13)
D ioestrus 7-00 ± 0 .51 (9)
V alues are m ean ± S.E.M., n  = number of observations.
ADR Proestrus
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FIGURE 6 : Log. concentration response curves to adrenaline, 
in the rat isolated uterus in proestrus: Controls; in
presence of azapetine (AZA, 10“6 M); in presence of 
desipramine (DMI, 10“” M) and normetanephrine (NMN. 10"^ M) 
in presence of AZA with DMI and NMN (all at 10“6 M;.
Number of observations in brackets.
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FIGURE 7: Log. concentration response curves to adrenaline, 
in the rat isolated uterus in oestrus: Controls; in
presence of azapetine (AZA, 10“ 6 M); in presence of 
desipramine (DMI, 10“6 M) and normetanephrine (NMN, 1 0 “ 6 m) 
in presence of AZA with DMI and NMN (all at 10”6 M).
Number of observations in brackets.
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FIGURE 8: Log. concentration response curves to adrenaline, 
in the rat isolated uterus in metoestrus: Controls; in
presence of azapetine (AZA, 10“6 M); in presence of desipramine 
(DMI, 10“6 M) and normetanephrine (NMN, 10“° M); in presence 
of AZA with DMI and NMN (all at 10“6 M). Number of 
observations in brackets.
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FIGURE 9: Log. concentration response curves to adrenaline, 
in the rat isolated uterus in dioestrus: Controls; in
presence of azapetine (AZA, 10”6 m ); in presence of 
desipramine (DMI, 10“^ M) and normetanephrine (NMN. 10“6 m ) 
in presence of AZA with DMI and NMN (all at 10"^ M).
Number of observations in brackets.
Table 5:
A drenaline potency in uteri from the four p h ases  
of the oestrous cycle (pD2 values).
P hase Potency (pD2 ) (n)
Pro estrus 7.22 * 0-30 (7)
O estrus 8.22 ± 0 .1 5 (16)
M etoestrus 8.10 ± 0 .1 7 (13)
d ioestru s 8 .1 6 + 0 .1 8 (9)
V alues are m ean ± S.E.M., n  = num ber of observations.
proestrus, 30%; oestrus, 45%; metoestrus, 30% and 
dioestrus, 40%. Uteri from the oestrus phase were most 
sensitive to the inhibitory effects of ADR (Table 5).
(c) Salbutamol
Concentration-response curves and pD 2 values for SAL
in proestrus, oestrus, metoestrus and dioestrus are shown
in Figures 10 to 13, and Table 6 , respectively. SAL (10~"9M 
— 5- 10 M) produced concentration-related inhibition of the 
standard Ach evoked contraction in the four phases of the 
oestrus cycle. The maximum degrees of inhibition produced 
during the oestrous cycle was approximately: proestrus,
35%; oestrus, 65%; metoestrus, 100% and dioestrus, 40%. 
Uteri in the oestrus phase were the least sensitive to the 
inhibitory effects of SAL (Table 6 ).
The degrees of inhibition produced by NA, ADR and SAL, 
and their corresponding pD2 values varied throughout the 
oestrous cycle. While the maximum response to NA and ADR 
never exceeded 45% inhibition of the ACH induced 
contraction, that produced by SAL reached 65% in oestrus 
and 100% in metoestrus. During the oestrous cycle, uteri 
from the oestrus phase were most sensitive to the 
inhibitory effects of NA and ADR and least sensitive to 
SAL. Interestingly, SAL displayed a lower potency in 
oestrus when compared to the other 3 phases, in which 
salbutamol and adrenaline were significantly more potent 
than noradrenaline as indicated by the pD 2 values.
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FIGURE 10: Log. concentration response curves to salbutamol 
in the rat isolated uterus in proestrus: Controls; in
presence of azapetine (AZA, 10“  ^M); in presence of 
desipramine (DMI, 10“  ^M) and normetanephrine (NMN, 10“° M) 
in presence of AZA with DMI and NMN (all at 10"^ M).
Number of observations in brackets.
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FIGURE 11: Log. concentration response curves to Salbutamol, 
in the rat isolated uterus in oestrus: Controls; in presence
of azapetine (AZA, 10”6 M); in presence of desipramine (DMI, 
10“6 M) and normetanephrine (NMN. 10"6 M); in presence of 
AZA with DMI and NMN (all at 10 M). Number of observations
in brackets.
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FIGURE 12: Log. concentration response curves to Salbutamol, 
in the rat isolated uterus in metoestrus: Controls; in
presence of azapetine (AZA, 10“6 M); in presence of desipramine 
(DMI, 10”° M) and normetanephrine (NMN, 10~° M); in presence 
of AZA with DMI and NMN (all at 10"6 M). Number of 
observations in brackets.
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FIGURE 13: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in dioestrus: Controls; in
presence of azapetine (AZA, 10"^ m ); in presence of 
desipramine (DMI, 10~6 M) and normetanephrine (NMN, 10"^ M) 
in presence of AZA with DMI and NMN (all at 10”  ^ M).
Number of observations in brackets.
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Table 6:
S a lb u ta m o l p o ten cy  in  u teri from  th e  four  
p h a ses  o f the oestrous cycle (pD2 values).
P hase Potency (pD2) (n)
Proestrus 7.82 - 0.20 (7)
O estrus 7.16 ± 0.04 (16)
M etoestrus 7.10 ± 0 .2 3 (13)
D ioestrus 7-82 ± 0.04 (9)
V alues are m ean ± S.E.M., n  = num ber of observations.
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(C) RESPONSES TO ADRENOCEPTOR AGONISTS IN THE PRESENCE OF
AN C* -RECEPTOR ANTAGONIST AND UPTAKE INHIBITORS IN 
THE FOUR PHASES OF THE OESTROUS CYCLE
The observed differences in both potency and degree of 
inhibition produced by the agonists during the oestrous 
cycle might have been due to:
(i) The presence of CX -excitatory receptors, which could 
oppose the inhibition produced by NA and ADR. Indeed, 
there was some evidence for this effect as these drugs 
produced motor responses in some phases of the oestrous 
cycle.
(ii) The presence of avid amine removal mechanisms into 
neuronal and/or non-neuronal tissues which could affect the 
responses to all the agonists.
Therefore, three series of experiments were performed 
in the presence of: (a) an -receptor antagonist, (b)
inhibitors of both amine removal mechanisms, and (c) an 
oi-receptor antagonist, and inhibitors of both amine removal 
mechanisms.
(1) MOTOR RESPONSES
In proestrus and oestrus, both NA and ADR in the
concentration range (10" 6  M to 3 x 1CT5  M) produced small 
contractile responses. Unlike the Ach motor responses 
which were rapid in onset and sustained, the NA and ADR 
motor responses had a slow onset, with a latency of 1 0
seconds and a duration of only 1 0  seconds and showed very
rapid tachyphylaxis. The motor responses were not
concentration-related, and were abolished by the o< - 
receptor antagonist, Azapetine (10- 6  M).
(2) INHIBITORY RESPONSES TO NA. ADR AND SAL IN THE 
PRESENCE OF AN C* -RECEPTOR ANTAGONIST 
In the first series of experiments, the inhibitory 
responses were re-examined in the presence of Azapetine 
(AZA, 10- 6  M) which was chosen since it had no effect on 
the Ach-induced contraction (Digges, 1980; Ohia, 1986).
(a) Noradrenaline
Concentration-response curves and pD 2 values for NA in 
proestrus, oestrus, metoestrus and dioestrus are shown in 
Figures 2 to 5, and Table 7 respectively. AZA enhanced 
significantly (P < 0.01) the maximum degree of inhibition 
produced by NA in proestrus, oestrus, and dioestrus. In 
contrast, AZA had no significant effect on the NA response 
in the metoestrus phase. Compared with control values, 
there were no significant differences in the pD2 values for 
NA after AZA treatment. (Table 7).
(b) Adrenaline
Concentration-response curves and pD 2 values for ADR 
in proestrus, oestrus, metoestrus and dioestrus are shown 
in Figures 6  to 9 and Table 8  respectively. Unlike NA, AZA 
had no significant effect on the maximum degree of 
inhibition produced by ADR during the oestrus cycle. 
However, there was a significant (P < 0.001) shift in the 
ADR concentration-response curves to the right, at the
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Table 7:
Effect of A zapetine (AZA, 10" ^ M) on noradrenaline  
potency in  uteri from the four phases of the oestrous  
cycle (pD2 values).
Potency (pD2)
Phase Control (n) After Aza(n)
Proestrus
O estrus
M etoestrus
D ioestrus
6.92 ± 0.51 (7) 
7.40 ± 0 .0 9  (16) 
6.70 ± 0.08 (13) 
7-00 ± 0 .5 1  (9)
6.82 ± 0 .25 (8) 
7 . 1 5 ± 0 .12 (4) 
6.70 ± 0 .2 1  (8) 
6.96 ± 0 .04  (4)
Values are m ean ± S.E.M., n  = number of observations.
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Table 8:
Effect of A zapetine (AZA, 10" ^ M) on A drenaline  
p oten cy  in  u teri from the four p h a ses  o f th e  
oestrous cycle (pD2 values).
Phase
Potency (pD2)
Control (n) After Aza(n)
Proestrus
O estrus
M etoestrus
D ioestrus
7.22 ± 0-30 (7)
8.22 ± 0 .15 (16) 
8.10 ± 0 .1 7  (13) 
j*. 16 ± 0 .1 8  (9)
7.40 ± 0 .2 4  (11) 
8.10 ± 0 .1 5  (17) 
8*16 ± 0 .2 5  (11) 
7 2 2  ± 0 .80  (8)
Values are m ean ± S.E.M., n  = number of observations.
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Table 9:
Effect of Azapetine (AZA, 10" ^ M) on Salbutam ol 
potency in uteri from the four p h a ses  of the  
oestrous cycle (pD2 values).
Phase
Potency (pD2)
Control (n) After AZA (h)
Proestrus 7.82 ± 0.20 (7) 7.52 ± 0.22 (12)
Oestrus 7.16 ± 0 .0 4  (16) 7.10 ± 0 .0 4  (12)
Metoestrus 7.10 ± 0 .2 3  (13) 7.15 ± 0.76 (6)
Dioestrus 7.82 + o.04 (9) 7.82 + 0.36 (8)
Values are mean ± S.E.M., n  = number of observations.
lower concentrations, in oestrus and dioestrus. Compared 
with control values, there were no significant differences 
in the pD 2 values for ADR after AZA treatment (Table 8 ).
(c) Salbutamol
Concentration-response curves and pD 2 values for SAL 
in proestrus, oestrus, metoestrus and dioestrus are shown 
in Figures 10 to 13 and Table 9, respectively. AZA had no 
significant effect on SAL concentration-response curves in 
any phase of the oestrous cycle and there were no 
significant differences in the pD2 values for SAL after AZA 
treatment (Table 9) .
£X -receptor blockade increased the maximum degree of 
inhibition produced by NA in proestrus, oestrus and 
dioestrus, but had no effect on ADR and SAL responses. 
Shifts in the ADR concentration-response curves to the 
right were observed at the lower concentration in oestrus 
and dioestrus. £X -receptor antagonism had no effect on 
NA, ADR and SAL potency throughout the oestrous cycle.
(3) INHIBITORY RESPONSES TO NA. ADR AND SAL IN THE PRESENCE 
OF INHIBITORS OF NEURONAL AND EXTRA-NEURONAL UPTAKE 
MECHANISMS
In the second series of experiments DMI, (10~^ M) and 
NMN, (icT6  M) were used to inhibit neuronal and 
extraneuronal uptake respectively.
(a) Noradrenaline
Concentration-response curves and pD2 values for NA in 
proestrus, oestrus, metoestrus and dioestrus are shown in
Table 10:
Effect of Desipramine (DMI, 10'^M) and 
Normetanephrine (NMN, 10'^M) on noradrenaline 
potency in uteri from the four phases of the 
oestrous cycle (pD2 values).
Phase
Potency (pD2 )
Control (n) After DMI + N M N  (n)
Proestrus
Oestrus
Metoestrus
Dioestrus
6.92+0.51 (7) 
7.40 ±0.09 (16) 
6.70 ±0.08(13) 
7.00 ± 0.51 (9)
7.22 + 0.40 (12) 
7.52 ± 0.26 (12) 
7.46 ±0.14 (12)*** 
7.15 ±0.04(8)
Values are mean ± S.E.M., n  = num ber of observations.
Table 11:
Effect of Desipramine (DMI, 10" ^ M) and 
normetanephrine (NMN, 10" 6M) on Adrenaline 
potency in uteri from the four phases of the 
oestrous cycle (pD2 values).
Phase
Potency (pD2 )
Control (n) After DMI + N M N  (n)
Proestrus
Oestrus
Metoestrus
Dioestrus
7.22 ± 0.30 (7)
8.22 + 0.15 (16) 
8.10 ±0.17 (13) 
8.16 + 0.18(9)
8.30 + 0.08 (12) 
8.00 ± 0.29 (12) 
8.22 ± 0.33 (6)
8.30 ± 0.16 (8)
Values are mean ± S.E.M., n  = num ber of observations.
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Figures 2 to 5 and Table 10, respectively. DMI and NMN 
shifted NA concentration-response curves to the left, and 
enhanced significantly (P < 0.001) its maximum degree of 
inhibition. Compared with the control value, there was a 
significant increase (P < 0.001) in the pD 2 value for NA in 
metoestrus, in the presence of DMI and NMN (Table 10) .
(b) Adrenaline
Concentration-response curves and pD2 values for ADR 
in proestrus, oestrus, metoestrus and dioestrus are shown 
in Figures 6  to 9 and Table 11, respectively. DMI and NMN 
shifted ADR concentration-response curves to the left, and 
enhanced significantly (P < 0.001) its maximum degree of 
inhibition. ADR now produced a complete inhibition of the 
Ach-induced contraction in all phases. Compared with 
control values, there were no significant differences in 
the pD 2 value for ADR in the presence of DMI and NMN (Table 
11) .
(c) Salbutamol
Concentration-response curves and pD 2 values for SAL 
in proestrus, oestrus, metoestrus and dioestrus are shown 
in Figures 10 to 13 and Table 12, respectively. DMI and 
NMN shifted SAL concentration-response curves to the left 
(all phases), and enhanced significantly (P < 0.001) its
maximum degree of inhibition in proestrus, oestrus and 
dioestrus. SAL now produced a complete inhibition of the 
Ach contraction in all phases of the oestrous cycle. 
Compared with the control value, there was a significant
87
Table 12:
Effect of Desipram ine (DMI, 10"^M) and 
Normetanephrine (NMN, 10" ^ M) on Salbutamol 
potency in uteri from the four phases of the 
oestrous cycle. (pD2 values).
Potency (pD2)
Phase Control After DMI + NMN (n)
Proestrus
Oestrus
Metoestrus
Dioestrus
7.82 ± 0.30 (7) 
7.16 ±0.04(16) 
7.10 ±0.23(13)
7.82 ±0.04(9)
7.60 ± 0.06 (12) 
8.30 +0.12  (12)*** 
8.22 ±0.11 (6)
7.82 + 0.29 (8)
Values are mean ± S.E.M., n = number of observations.
increase (P < 0.001) in the PD2 value for SAL in oestrus, 
in the presence of DMI and NMN (Table 12) .
Blockade of agonist uptake processes shifted 
concentration-response curves produced by all three 
agonists to the left and enhanced their maximum degrees of 
inhibition throughout the oestrous cycle. Furthermore, 
there were significant increases in NA and SAL potency in 
metoestrus and oestrus phases, respectively. However, 
shifts in agonist concentration-response curves were not 
always reflected/in pD9 values.
(4) INHIBITORY RESPONSES TO NA, ADR AND SAL IN THE COMBINED 
PRESENCE OF BOTH AN Q( -RECEPTOR ANTAGONIST AND 
INHIBITORS OF NEURONAL AND EXTRANEURONAL UPTAKE 
MECHANISMS
In the third series of experiments both -receptor
activity, and neuronal and extraneuronal uptake mechanisms 
were prevented with AZA (10~ 6 M) , DMI (10 6  M) and NMN 
10~ 6  M) , respectively.
(a) Noradrenaline
Concentration-response curves and PD2 values for NA in 
proestrus, oestrus, metoestrus and dioestrus are shown in 
Figures 2 to 5 and Table 13, respectively. The combined 
antagonists shifted NA concentration-response curves to the 
left, and enhanced significantly (P < 0 .0 0 1 ) its maximum 
degree of inhibition. Compared with the control value, 
there was a significant increase (P < 0 .0 0 1 ) in the pD 2
value for NA in metoestrus, in the presence of the combined
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Table 13:
Effect of Azapetine (AZA, 10'^M), Desipramine (DMI, 
10"6m) and Normetanephrine (NMN, 10'^M) on 
Noradrenaline potency in uteri from the four phases of 
the Oestrous cycle (pD2 values).
Phase
Potency (pD2 )
Control After DMI + N M N  + AZA (n)
Proestrus 6.92 ±0.51 (7) 7.22 ±0.29 (12)
Oestrus 7.40 + 0.09(16) 7.15 ±0.10(12)
Metoestrus 6.70 + 0.08 (13) 7.40 ± 0.11 (6) ***
Dioestrus 7.00 + 0.51 (9) 7.15 ±0.7(8)
Values are mean ± S.E.M., n = number of observations.
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antagonists (Table 13).
(b) Adrenaline
Concentration-response curves and pD 2 values for ADR 
in proestrus, oestrus, metoestrus and dioestrus are shown 
in Figures 6  to 9, and Table 14, respectively. The 
combined antagonists enhanced significantly (P < 0.001) ADR 
maximum degree of inhibition in all phases. ADR produced a 
complete inhibition of the Ach evoked contraction 
throughout the oestrous cycle. Compared with controls, 
there were no significant differences in the pD 2 values for 
ADR in the presence of the combined antagonists (Table 14).
(c) Salbutamol
Concentration-response curves and pD2 values for SAL 
in proestrus, oestrus, metoestrus and dioestrus are shown 
in Figures 10 to 13 and Table 15, respectively. The 
combined antagonists shifted SAL concentration-response 
curves to the left and enhanced significantly (P < 0.001) 
its maximum degree of inhibition. SAL gave a complete 
inhibition of the Ach induced contraction in all phases. 
Compared with control values, there were no significant 
differences in the PD2 values for SAL in the presence of 
the combined antagonists (Table 15).
In the presence of combined —receptor and uptake 1
and uptake 2 antagonists, the maximum degrees of inhibition 
produced by NA, ADR and SAL were increased in all phases of 
the cycle. Except for ADR, agonists concentration-response 
curves were also shifted to the left. The effects produced
91
Table 14:
Effect of Azapetine (AZA, lO'^M), Desipramine (DMI, 
10"^M) and Normetanephrine (NMN, 10"^M), on 
Adrenaline potency in uteri from the four phases of the 
oestrous cycle (pD2 values).
Phase
Potency (pD2)
Control After DMI + NMN + A2A (n)
Proestrus 7.22 + 0.30 (7) 8.22 ±0.12 (12)
Oestrus 8.22 ±0.15916) 8.00 ± 0.29 (12)
Metoestrus 8.10 ±0.17 (13) 8.16 ±0.36 (6)
Dioestrus 8.16 ±0.18 (9) 8.22 ±0.04 (8)
Values are mean ± S.E.M., n = number of observations.
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Table 15:
Effect of Azapetine (AZA, 10”^ M) Desipram ine (DMI, 
10" 6M) and Normetanephrine (NMN, 10" ^ M) on 
salbutamol potency in uteri from the four phases of the 
oestrous cycle (pD2 values).
Potency (pD2)
Phase Control After DMI + NMN + AZA (n)
Proestrus
Oestrus
Metoestrus
Dioestrus
7.82 ± 0.30 (7) 
7.16 ±0.04(16) 
7.10 ±0.23(13)
7.82 ±0.04(9)
7.52± 0.20 (4) 
7.82 ±0.29 (4)
8.00 ± 0.41 (4)
8.00 + 0.02 (4)
Values are mean ± S.E.M., n = number of observations.
by the combined receptor and uptake antagonists were no 
greater than those achieved in the presence of neuronal and 
extraneuronal blockade.
(D) RESPONSES TO fa -ADRENOCEPTOR AGONISTS IN THE PRESENCE 
OF A CYCLOOXYGENASE INHIBITOR
An effect leading to the generation of excitatory 
prostaglandins by fa -adrenoceptor agonists may 
functionally antagonize their inhibitory response. In two 
series of experiments, prostaglandin biosynthesis was 
prevented using FBF, a cyclo-oxygenase inhibitor. FBF 
(10- 5  M) had no effect on the Ach induced contraction. 
Concentration-response curves were constructed for SAL 
during the oestrous cycle in the absence of uptake 
blockers, and AZA (control I, see Methods, Section Fi.5) 
and in the presence of AZA (10  ^ M) , DMI (10  ^ M), and NMN 
(10- 6  M) (control II, see Methods, Section Fi.4).
(E) INHIBITORY RESPONSES TO SALBUTAMOL IN THE PRESENCE OF 
A CYCLO-OXYGENASE INHIBITOR IN THE FOUR PHASES OF THE 
OESTROUS CYCLE
Concentration-response curves and PD 2 values for SAL 
in the absence and presence of FBF are shown in Figures 15 
to 2 2 and Table 16, respectively.
PROESTRUS;
FBF shifted significantly (P < 0.001) the control I 
concentration-response curve to the left (Figure 15) . 
While, in control II experiments, FBF produced no further
3k
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Log Con. (SAL) (M)
FIGURE 15: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in proestrus: Controls; in
presence of flurbiprofen (FBF, 1CT-5 M). Control I = SAL alone. 
Number of observations in brackets.
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FIGURE 16: Log concentration response curves to Salbutamol 
in the rat isolated uterus in proestrus: Control II =
SAL, in presence of AZA (10“6 M); DMI (10“6 M) and NMN (10”6 M); 
in presence of AZA (10”6 M), DMI (10”6 M), NMN (10”^ M) and 
FBF (10“5 M). Number of observations in brackets.
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FIGURE 17: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in oestrus: Controls, and in
presence of flurbiprofen (FBF, 10~5 M). Control I = SAL alone. 
Number of observations in brackets.
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FIGURE 18: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in oestrus: Control II = SAL, 
in presence of AZA (10”6 M), DMI (10”6 M) and NMN (10”6 M); 
in presence of AZA (l0“6 M), DMI (10”6 m ), NMN (10”® M) and 
FBF (10“5 M). Number of observations in brackets.
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FIGURE 19: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in metoestrus: Controls, and in
presence of flurbiprofen (FBF, 10”^ M). Control I = SAL alone. 
Number of observations in brackets.
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FIGURE 20: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in metoestrus: Control II = SAL
in presence of AZA (10"6 M), DMI (10“6 anci (io-6 M); 
in presence of AZA (10~6 m), DMI (10“° M), NMN (10"° M) ana 
FBF (10“5 M). Number of observations in brackets.
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FIGURE 21: Log. concentration response curves to Salbutamol, 
in the rat isolated uterus in dioestrus: Controls, and in
presence of flurbiprofen (FBF, 10“5 M). Control I = SAL alone. 
Number of observations in brackets.
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FIGURE 22: Log. concentration response curves to Salbutamol, 
in the rat isolated uterus in dioestrus: Control II = SAL in
presence of AZA (10“£ M), DMI (10-;? M) and NMN (10“6 M); in 
presence of AZA (10"6 M), DMI (10”° M), NMN (10-6 M) and 
FBF (10-5 m ). Number of observations in brackets.
T able 16:
Effect of Kurbiprofen (FBF, 10'^M), on Salbutamol potency in 
uteri from the four phases of the oestrous cycle (pD2 values).
Potency (pD2)
Phase Experiment After FBF
Proestrus Control I 
Control II
7.82 ± 0.20 (7) 
8.30 ± 0.20 (4)
8.70 ±0 .60  (6)
8.70 ± 0.03 (6)
Oestrus Control I 
Control II
7.22 ±0.04(16) 
8.52 ± 0.29 (4)
8.70 ± 0.09 (6) ***
8.70 ±0.02 (6)
Metoestrus Control I 
Control II
8.00 ±0.23(13) 
8.82 ‘±0.41 (4)
8.82 ± 0.04 (6) ** 
9.15  ±0.23 (6)
Dioestrus Control I 
Control II
8.00 ± 0.04 (9) 
8.52 ± 0.02 (4)
8.70 ±0.02 (6) 
8.60 ± 0.04 (6)
Values are mean ± S.E.M., n = number of observations.
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increase in the responses to SAL (Fig. 16) and there was no 
change in the pD 2 values (Table 16) .
OESTRUS:
FBF shifted the control I concentration-response curve 
to the left, and enhanced significantly (P < 0.001) the
maximum degree of inhibition (Figure 17). In control II 
experiments, only a slight but non-significant shift in the 
concentration-response curve was achieved (Figure 18). In 
control I experiments, there was a significant increase (P 
< 0.001) in the pD2 values for SAL, in the presence of FBF 
(Table 16). In contrast, there was no significant 
difference in the control II pD2 value for SAL.
METOESTRUS:
FBF shifted significantly (P < 0.001) both control I 
and control II concentration-response curves to the left, 
and enhanced significantly (P < 0.001) the maximum degree 
of inhibition (Figures 19 and 20) . In control I 
experiments, there was a significant increase (P < 0.001) 
in the pD 2 values for SAL, in the presence of FBF (Table 
16) . In contrast there was no significant difference in the 
control II pD 2 value for SAL.
DIOESTRUS:
FBF shifted the control I concentration-response curve 
to the left, and enhanced significantly (P < 0 .0 0 1 ) the
maximum degree of inhibition (Figure 21) . In control II 
experiments (Figure 22), only responses to the higher 
concentrations of SAL were enhanced significantly (P <
104
0.01) . There were no significant differences in the 
control I and control II pD 2 values for SAL, in the 
presence of FBF (Table 16) .
In general, cyclo-oxygenase inhibition shifted the SAL 
concentration-response curves to the left, and enhanced its 
maximum degree of inhibition. However, the effects 
produced by cyclo-oxygenase inhibition were less under the 
control II situation.
(F) RESPONSES TO A &  -ADRENOCEPTOR AGONIST IN OESTROGEN 
PRETREATED ANIMALS
In order to induce a particular phase of the oestrous 
cycle, animals can be pretreated with oestrogen or 
progesterone. Since differences in the degree of uterine 
inhibition produced by the adrenoceptor agonists during the 
oestrous cycle persisted even when ^  -receptors were 
blocked and uptake mechanisms were prevented, a series of 
experiments was performed to investigate the role of the 
ovarian hormones. Animals were pretreated with 17/^ -
oestradiol ( 1  mg/kg) to induce oestrus, which was confirmed 
by examination of vaginal smears. In the oestrogen 
pretreated rats, Ach produced greater tension (5.20 + 
0.62g, n = 12) than in naturally occurring oestrus (4.90 ± 
0.57g, n = 14) . As in the four stages of the oestrous 
cycle and in the pregnant and post-partum rats, there was 
no significant difference between the pD2 values for Ach m  
the oestrogen pretreated and natural oestrus rats, (8.36 ± 
0.21, n = 12 and 8.29 ± 0.20, n = 14 respectively).
(i) INHIBITORY RESPONSES TO SALBUTAMOL, ISOPRENALINE AND
ISOXSUPRINE IN UTERI FROM OESTROGEN PRETREATED ANIMALS
The effects of selective £> -adrenoceptor agonists 
SAL (ft 2 ) ' isoPrenaline ( / 1  /? 2  ^ anc^  isoxsuprine 
(ft 1  2  ^ were examined in the absence and presence of the
cyclo-oxygenase inhibitor, FBF.
Concentration-response curves and pD 2 values for SAL, 
ISO, and ISOX in the absence and presence of FBF are shown 
in Figures 23 to 25 and Table 17, respectively:
Salbutamol:
The SAL concentration response curves in uteri from 
oestrogen primed animals lay to the left of those obtained 
in natural oestrus, and the pD2 values for SAL
were 9.30 ± 0 . 4 3  (n = 6 ) in oestrogen treated animals and 
8.42 + 0.04 (n = 16) in natural oestrus. Thus uteri from 
oestrogen pretreated animals appear to be more sensitive to 
the inhibitory effect of SAL. AZA (10 6  M) , DMI (10 M) 
and NMN (10~ 6  M) had no significant effect on the SAL 
response, and in subsequent experiments these drugs were 
not present, i.e. the experiments were all of the control I
class.
FBF increased significantly (P < 0.01) the responses 
to SAL enhancing its maximum degree of inhibition (Figur 
23). compared with the control value, there was no 
significant difference in SAL PD2 value in the presence of
FBF (Table 17).
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10"9M 10 8m
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FIGURE 23: Log. concentration response curves to Salbutamol, 
in the rat isolated uterus in oestrogen pretreated:
Controls, and in presence of flurbiprofen (FBF, 10“5 M). 
Number of observations in brackets.
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FIGURE 24: Log. concentration response curves to isoprenaline 
in the rat isolated uterus in oestrogen pretreated: Controls,
and in presence of flurbiprofen (FBF, 10"^ M). Number of 
observations in brackets.
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FIGURE 25: Log. concentration response curves to Isoxsuprine 
in the rat isolated uterus in oestrogen pretreated: Controls,
and in presence of flurbiprofen (FBF, lO”-* M). Number of 
observations in brackets.
Table 17:
Effect o f Flurbiprofen (FBF, 10"^M) on Sal, Iso and Isx 
potencies in uteri from oestrogen pretreated anim als 
(pD2 values).
Drug
Potency (pD2)
Control After FBF (n)
Salbutam ol 8.10 ± 0 .4 3 (6 ) 8.40 ± 0 .14  (6)
Isoprenaline 8.52 ± 0.22 (6) 8.70 ± 0 .33  (6)
Is ox suprine 6.30 + 0.55 (6) 6.52 ± 0 .47  (6)
Values are m ean ± S.E.M., n = number of observations.
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Isoprenaline:
ISO was of equal potency and effectiveness with SAL in 
inhibiting Ach. FBF increased significantly (p < 0.05) 
isoprenaline responses, enhancing its maximum degree of 
inhibition (Figure 24). Compared with the control value, 
there was no significant difference in isoprenaline pD2  
value in the presence of FBF (Table 17).
Isoxsuprine:
ISOX was significantly less potent and effective than 
SAL + ISO in inhibiting Ach. FBF caused no significant 
changes in the ISOX concentration-response curve (Figure 
25) , and pD 2 value (Table 17). Thus while cyclo-oxygenase 
inhibition enhanced SAL, and ISO responses in uteri from 
oestrogen pre-treated animals, there was little or no 
effect on the isoxsuprine response.
(G) RESPONSES TO A -ADRENOCEPTOR AGONIST IN THE
PRESENCE OF A PHOSPHOLIPASE A, INHIBITOR 
The possible involvement of intramurally generated 
prostaglandins in uterine response to A  -adrenoceptor 
agonists was further investigated in a series of 
experiments in which Quinacrine was used to inhibit 
phospholipase A2, the enzyme which releases arachidonic
—  C
acid from ester pools. Quinacrine (10 M) had no effect 
on the motor response to Ach, in uteri from oestrogen 
pretreated animals. Quinacrine increased the SAL responses 
significantly (P < 0.01) and enhanced its maximum degree of 
inhibition (Figure 26) .
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FIGURE 26: Log. concentration 
in the rat isolated uterus in 
and in presence of Quinacrine 
in brackets.
response curves to Salbutamol 
oestrogen pretreated: Controls,
(IQ-5 Number of observations
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P ^ 2  values obtained in the absence and presence of 
Quinacrine was <8.16 ± 0.43 (n = 6 ) and 8.25 ± 0.28 (n = 6 ) 
respectively. There was no significant difference in the 
PD 2  value for SAL in the presence of Quinacrine.
Inhibition of phospholipase A 2 produced effects 
similar to that observed in the presence of FBF confirming 
a role for prostaglandins in the adrenoceptor agonist 
inhibitory response.
(H) RESPONSES TO A ft -ADRENOCEPTOR AGONIST IN THE 
COMBINED PRESENCE OF A CYCLO-OXYGENASE INHIBITOR AND 
ARACHIDONIC ACID 
Since arachidonic acid is the substrate for cyclo- 
oxygenase, a series of experiments was performed to 
determine if the effects produced by the cyclo-oxygenase 
inhibitor, FBF, can be reversed by addition of exogenous 
arachidonic acid. Arachidonic acid (10 M) had no effect 
on Ach—induced contraction in uteri from oestrogen 
pretreated animals. Arachidonic acid alone was also 
without effect on the SAL responses. FBF increased 
significantly (P < 0.001) SAL responses and enhanced its 
maximum degree of inhibition. The shift of the SAL 
concentration-response curve induced by FBF was unaffected
by arachidonic acid (Figure 27) .
The effect produced by cyclo-oxygenase inhibition on
adrenoceptor agonists responses was not reversed in the 
presence of arachidonic acid.
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FIGURE 27: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in oestrogen pretreated: 
Controls, in presence of (FBF, 10”  ^M) and then in presence 
of (FBF, 1CT5 M), and arachidonic acid (AA 10“6 M).
Number of observations in brackets.
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(!) RESPONSES TO ADRENOCEPTOR AGONISTS IN UTERI FROM 2 0 -DAY 
PREGNANT ANIMAT,S
So far, the responses to the adrenoceptor agonists and 
the effects of cyclo-oxygenase inhibition have been 
examined m  uteri from animals undergoing the natural 
oestrous cycle and from oestrogen pretreated rats. It was, 
therefore, of interest to re-examine these effects in uteri 
from rats in late pregnancy.
(i) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL
ADR (10- 9  M - 10' 6 M) and SAL (10”9M - 3 x 10” 7 M) 
produced concentration-related inhibition of Ach-induced 
contraction in both control I and control II studies 
(Figures 28 and 29) . In both Control I and II 20 day 
pregnant rats, ADR and SAL were more potent, than that in 
the non-pregnant rats, the pD 2 values were also 
significantly greater. The agonists were also more 
effective in inhibiting the responses to ACH. ADR and SAL 
in Control I produced 60% inhibition, while in Control II 
ADR produced 80% and SAL 90% respectively. Whereas in the 
non—pregnant rats the maximum degree of inhibition was 45% 
achieved in oestrus. For both ADR and SAL, there was a 
significant increase (P < 0.01) in their maximum degrees of 
inhibition under the control II situation. There was, 
however, no significant difference between the control I 
and control II pD2 values for ADR and SAL (Table 18) .
(ii) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL
IN THE PRESENCE OF A CYCLO-OXYGENASE INHIBITOR
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FIGURE 28: Log. concentration response curves to adrenaline 
in the rat isolated uterus in 20 day pregnant:
Control I = ADR alone. Control II = ADR, in presence of 
AZA (10"6 M), DMI (10"6 M) and NMN (10-6 M). Number of 
observations in brackets.
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FIGURE 29: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 20 day pregnant:
Control I = SAL alone; Control II = SAL. in presence of 
AZA (10“° DMI (10"° M) and NMN (10“& M). Number of 
observations in brackets.
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Table 18:
Adrenaline and Salbutam ol potency in uteri from 
20-day  pregnant anim als (pD2 values).
Potency (pD2 )
Experim ent ADR SAL
Control I 
Control II
7.70 ±0 .1 9  (13) 
7.30 ± 0.37 (6)
7.82
7.70
± 0 . 1 9  (14) 
± 0 .24  (6)
Values are m ean ± S.E.M., n = number of observations.
a .urf', -i . L-inaraaa.a'f 
■ at r;v4 : 1 -■ . * ><■£ 1 1 - ^  ^ : v
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Concentration-response curves to ADR and SAL were
obtained in the absence (control I experiments) and
presence (control II experiments) of the combined
antagonists, and cyclo-oxygenase activity was inhibited by 
—5
FBF (10 M). Concentration-response curves and PD2 values 
for the agonists in the absence and presence of FBF are 
shown in Figures 30 to 33, and Table 19 respectively.
ADRENALINE:
In the presence of FBF, the concentration response 
curve to ADR in control I moved to the left, and there was 
an increase in the maximum degree of inhibition (Figure 
30) . However, although there was increased sensitivity to 
ADR, which reached significance at some concentrations 
(10“ 8  M and 3 x 10” 8 M) the pD2 values for ADR in the 
absence and presence of FBF did not differ significantly. 
A similar situation occurred in control II (Figure 31) but 
FBF produced no increase in the maximum degree of 
inhibition which had already been increased to 1 0 0 % by the 
uptake blockers.
SALBUTAMOL:
FBF shifted SAL concentration curves in both
control I and control II experiments to the left. 
Sensitivity to SAL at certain concentrations was increased 
significantly, but there was no significant difference in 
the pD 2 values for SAL in the absence and presence of FBF. 
As with ADR, the maximum degree of inhibition was increased 
by FBF only in the control I experiments.
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FIGURE 30: Log. concentration response curves to Adrenaline 
in the rat isolated uterus in 20 day pregnant:
Controls, and in presence of flurbiprofen (FBF, 10"5 M). 
Number of observations in brackets.
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FIGURE 31: Log. concentration response curves to Adrenaline
in the rat isolated uterus in 20 day pregnant:
Control II = ADR, in presence of AZA (10“6 M), DMI (10~6 M)
and NMN (10“6 M): in presence of AZA (10“6 M), DMI (10“  ^M),
NMN (10"° M) and FBF (10“5 M). Number of observations in 
brackets.
20 day pregnant uterus control I
CD
CO
CZ
o
§ 60-
FBF + SAL /
o
o
EE
Co ntrolzco*=c 40 -
4—O
CZ
o
o
xz
CZ
Log Con, o f  SAL (M)
FIGURE 32: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 20 day pregnant:
Controls, and in presence of flurbiprofen (FBF, 10"5 M). 
Number of observations in brackets.
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FIGURE 33: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 20 day pregnant:
Control II = SAL in presence of AZA (10“° M), DMI (10~6 M) 
and NMN (10”6 M); in presence of AZA (10“° M), DMI (10”° M), 
NMN (10“6 M and FBF (10“* M). Number of observations in 
brackets.
T ab le 19:
Effect of Flurbiprofen (FBF, 10'^M) on Adr and Sal 
potency in uteri from 20-day pregnant animals (pD2  
values).
Potency (pD2)
Drug Experiment After FBF
Adr Control I 7.52 ± 0.19 (13) 7.82 ± 0.13 (13)
Control II 7.40 + 0.37 (6) 7.60 ± 0.16 (6)
Sal Control I 8.00 + 0.19 (14) 8.10 ± 0.19 (14)
Control II 7.70 ± 0.24 (6) 8.10 ± 0.30 (6)
Values are mean ± S.E.M., n = number of observations
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FBF enhanced the activity of the adrenoceptor agonists 
in late pregnancy as it did in preparations from non­
pregnant and oestrogen pretreated animals but the extent of 
the effect was less in the pregnant animals.
(J) RESPONSES TO ADRENOCEPTOR AGONISTS IN UTERI FROM 
ONE-DAY POST-PARTUM ANIMALS
The possible involvement of intramurally generated 
prostaglandins in uterine response to adrenoceptor agonists 
was also investigated in post-partum animals.
(i) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL
ADR (10~9 M - 10-6 M) and SAL (10~9 M - 
3 x 10-7 M) produced concentration-dependent inhibition of 
Ach-induced contraction in both control I and control II 
studies (Figures 34 and 35) . In one day post partum rats, 
both ADR and SAL in Control I produced 90% inhibition, 
while in Control II ADR was less potent than SAL compared 
to non-pregnant and pregnant rats. In the non pregnant rats 
the maximum degree of inhibition was around 45% in oestrus, 
while in 2 0 day pregnant rats, ADR and SAL in Control I 
produced 60% inhibition, while in Control II, ADR produced 
80% and SAL 90% inhibition respectively. There were no 
significant differences between control I and control II 
concentration-response for ADR and SAL and in their pD2 
values (Table 20) .
(ii) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL IN
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FIGURE 34: Log. concentration response curves to adrenaline 
in the rat isolated uterus in 1 day post partum:
Control I = ADR, alone: and Control II = ADR, in presence 
of AZA with DMI and NMN (all at 10"° M). Number of 
observations in brackets.
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FIGURE 35: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 1 day post partum:
Control I = SAL, alone: and Control II = SAL, in presence 
of AZA with DMI and NMN (all at 10“° M). Number of 
observations in brackets.
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Table 20:
A drenaline and Salbutam ol potency in  u te ri 
from  one-day  post p a rtu m  an im als  (pD2 
values).
Potency (pD2)
Experim ent ADR SAL
Control I 7.70 ± 0-03 (6) 7.60 ± 0.07 (6)
Control II 7.70 ±0.21 (6) 7.52. ± 0 .1 5  (4)
Values are mean ± S.E.M., n = number of
observations.
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THE PRESENCE OF A CYCLO-OXYGENASE INHIBITOR
Concentration-response curves to ADR and SAL were
obtained in the absence (control I experiments) and
presence (control II experiments) of the combined
antagonists, and cyclo-oxygenase activity was inhibited by 
—5
FBF (10 M ) . Concentration response curves and pD 2 values 
for the agonists in the absence and presence of FBF are 
shown in Figures 36 to 39, and Table 21, respectively. 
ADRENALINE:
FBF did not produce any change in the concentration 
curve for ADR. ADR alone produced 100% inhibition and so 
no further increase was possible with FBF.
SALBUTAMOL:
FBF shifted both control I and control II 
concentration-response curves to the left (Figures 38 and 
39). In control I experiments, the shift was significant 
and there was a significant increase (P < 0.001) in the pD 2  
value for SAL, in the presence of FBF (Table 21) . In 
contrast, there was no significant difference in the 
control II pD 2 value for SAL (Table 21) .
As with uteri from pregnant animals, cyclo-oxygenase 
inhibition also enhanced SAL responses in preparations from 
post-partum animals. However, cyclo-oxygenase inhibition 
did not affect ADR inhibitory responses.
(K) RESPONSES TO ADPENOCEPTOR AGONISTS IN ENDOMETRIUM FREE
UTERI FROM 20-DAY PREGNANT ANIMA_LS
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FIGURE 36: Log. concentration response curves to adrenaline 
in the rat isolated uterus in 1 day post partum: Controls, 
and in presence of flurbiprofen (FBF, 10“-* M). Number of 
observations in brackets.
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FIGURE 37: Log. concentration response curves to adrenaline
in the rat isolated uterus in 1 day post partum:
Control II = ADR, in presence of AZA (10"6 M), DMI (10~6 m ),
and NMN (10”  ^M); in presence of AZA (10"6 m), DMI (10 M),
NMN (10"6 M) and FBF (10"5 M). Number of observations in
brackets.
1 day Post Partum uterus control I
— o
80 -
CD
COco
Q.
CO
CDl_
FBF + SAL /
Control
+->
OEE
O
CZo
4—’
CZ*1' I
Log Con. o f  SAL (M)
FIGURE 38: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 1 day post partum:
Controls, and in presence of flurbiprofen (FBF, 10" ^ M). 
Number of observations in brackets.
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FIGURE 39: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 1 day post partum:
Control II = SAL, in presence of AZA (10"° M), DMI (10"° M) 
and NMN (10”6 m ): in presence of AZA (10"^ M), DMI (10"° M), 
NMN (10"° m ) and FBF (10"5 M). Number of observations 
in brackets.
Table 21:
Effect of Flurbiprofen (FBF, 10~5M) on Adr and Sal
potencies in uteri, from one-day post partum animals 
fpD2  values).
Potency fpDg)
Drug Experiment After FBF
Adr Control I 
Control n
7.70 ± 0.03 (6) 
7.22 ± 0.21 (6)
7.70 ± 0.05 (6) 
7.30 + 0.03 (6)
Sal Control I 
Control II
7.60 ± 0.07 (6) 
7.52 ±0.15(4)
8-50 ± 0.28 (6)*** 
7.82 + 0.10(4)
Values are mean ± S.E.M., n  = number of observations.
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preparations in which the myometrial and endometrial layers 
were intact. The possibility that the endometrial layer 
may play a role in uterine response to adrenoceptor 
agonists was, therefore, investigated in a series of 
experiments, in which the endometrium was removed. Both 
control I and control II studies were performed for ADR and 
SAL in the absence and presence of the cyclo-oxygenase 
inhibitor FBF (10“5 M).
(i) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL IN 
ENDOMETRIUM FREE UTERI 
Concentration-response curves and pD2 values for the 
agonists in the absence and presence of endometrium are 
shown in Figures 40 and 41 and Table 22, respectively.
ADRENALINE:
Removal of the endometrium produced no change in the 
concentration response curve to ADR in control I 
experiments (Figure 40) .
SALBUTAMOL:
In the absence of endometrium in control I 
experiments, there was a significant shift (P < 0.05) in 
the SAL concentration-response curve to the right at the 
higher concentrations (Figure 41). Compared with values 
obtained in whole uteri, there was no significant 
difference in SAL PD2 values in the absence of endometrium
(Table 22).
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FIGURE 40: Log. concentration response curves to adrenaline 
in the rat isolated uterus in 20 day pregnant:
Controls, with and without endometrium. Number of observations 
in brackets.
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FIGURE 41: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 20 day pregnant:
Controls, with and without endometrium. Number of observations 
in brackets.
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Table 22:
Effect of endom etrium  removal on Adr and Sal 
potencies in uteri from 20-day pregnant animals (pD2
values).
Potency (pD2)
State of uterus ADR SAL
Normal 7.75 ±0.19 (13) 8.00 ± 0 .1 9  (14)
Endometrium-free 7.52 ± 0.34 (6) 7.82 ± 0.19 (6)
Values are m ean ± S.E.M., n  = num ber of observations.
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(ii) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL IN 
THE PRESENCE OF A CYCLO-OXYGENASE INHIBITOR 
Concentration-response curves and pD2 values for the 
agonists in the absence and presence of FBF are shown in 
Figures 42 to 45, and Table 23, respectively. 
a d r e n a l i n e :
FBF had no effect on control I or control II 
concentration-response curves to ADR in endometrium-free 
preparations (Figures 42 and 43). In control II 
experiments, before addition of FBF, ADR produced a
complete inhibition of the Ach motor response. Compared 
with control values, there were no significant differences 
in both control I and control II pD2 values for ADR, m  the 
presence of FBF (Table 23) .
SALBUTAMOL:
FBF had no effect on the SAL concentration response 
curves in control I experiments (Figure 44) . In control II 
experiments FBF significantly increased the sensitivity 
SAL at low concentration (Figure 45), but there was no
significant change in the pD2 value (Table 23).
-inhibition produced by SAL which 
not alter the degree of inhibition v
was already 100%.
^ ™ohrium removal caused slight changes 
In summary, endometrium
in uteri from 2 0-day pregnant 
in ADR and SAL responses in
. . cat. in control II
animals. With the exception of
• uiu^inn had no effect on
experiments, cyclo-oxygenase m h
in uteri under this 
adrenoceptor agonist responses in
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FIGURE 42: Log. concentration response curves to adrenaline 
in the rat Isolated uterus in 20 day pregnant:
Controls endometrium free, and in presence of flurbiprofen 
(FftF, 10"-* M), Niinber of observations in brackets.
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FIGURE 43: Log. concentration response curves to adrenaline 
in the rat isolated uterus in 20 day pregnant endometrium free, 
Control II = ADR, in presence of AZA (10“6 M), DMI (10"6 M) and 
NMN (10~° M); in presence of AZA (10“° M), DMI (10“6 M), NMN (10“° M) 
and FBF (10"^ M). Number of observations in brackets.
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FIGURE 44: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 20 day pregnant endometrip free, 
Control II = SAL, in presence of AZA (10“6 M), DMI (10"° M) and 
NMN (10“6 M): in presence of AZA (10”° M), DMI (10 M),
NMN (10“6 m ) and FBF (10~5 M). Number of observations in
brackets.
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FIGURE 45: Log. concentration response curves to Salbutamol
in the rat isolated uterus in 20 day pregnant: Controls,
endometrium free, and in presence of flurbiprofen (FBF, 10~5 M). 
Number of observations in brackets.
Table 23:
Effect of Flurbiprofen (FBF, 10'5M) on Adr and Sal 
potencies in endometrium-free uteri from 20-day 
pregnant animals (pD2 values).
Potency (pD2)
Drug Experiment After FBF
Adr Control I 
Control II
7.10 ±0.34 (6) 
7.00 ± 0.28 (6)
7.10 ±0.33 (0)
7.10 ±0.34 (6)
Sal Control I 
Control II
7.70 ±0.19 (6) 
7.92 ± 0.34 (6)
7.75 ± 0.09 (6) 
8JJL± 0.30 (6)
Values are mean ± S.E.M., n = number of observations.
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condition.
(L) RESPONSES TO ADRENOCEPTOR AGONISTS IN ENDOMETRIUM-FREE 
UTERI FROM ONE-DAY POST-PARTUM ANIMALS 
As with the studies on pregnant animals with 
endometrium-free uterine preparations, a corresponding 
series of experiments was performed in uteri from one-day 
post-partum rats. Both control I and control II 
experiments were carried out for ADR and SAL, in the 
absence and presence of the cyclo-oxygenase inhibitor, FBF 
(10-5 M) .
(i) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL
Concentration-response curves and pD2 values for the 
agonists in the absence and presence of endometrium are 
shown in Figures 46 and 47, and Table 24, respectively. 
ADRENALINE:
In the absence of endometrium, there was a shift in 
ADR concentration-response curves to the right and a 
significant decrease (P < 0.001) in the maximum degree of 
inhibition (Figure 46). Compared with values obtained in 
whole uteri, there was a significant decrease (P < 0.05) in 
ADR PD2 value, in the absence of endometrium (Table 24) .
SALBUTAMOL:
in the absence of endometrium, there was a significant 
shift (P < 0.001) in SAL concentration-response curves to
the right (Figure 47) but the degree of inhibition was not 
reduced. Compared with values obtained in whole uteri,
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FIGURE 46: Log. concentration response curves to Adrenaline 
in the rat isolated uterus in 1 day post partum:
Controls, with and without endometrium. Number of 
observations in brackets.
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FIGURE 47: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 1 day post partum:
Controls, with and without endometrium. Number of 
observations in brackets.
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Table 24:
E ffect of endom etrium  rem oval on Adr and S al 
potencies in uteri from one-day post partum anim als 
(pD2 values).
Potency (pD2)
State of uterus ADR SAL
Normal 7.70 ± 0.03 (6) 7.30 ± 0.07 (6)
Endometrium-free 7.02 ± 0.34 (6)* 7.60 ± 0.34 (6)*
V alues are m ean ± S.E.M., n  = num b er of observations.
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there was a significant (P < 0.05) decrease in SAL pD2
values, in the absence of endometrium (Table 24).
(ii) INHIBITORY RESPONSES TO ADRENALINE AND SALBUTAMOL IN
THE PRESENCE OF A CYCLO-OXYGENASE INHIBITOR
Concentration-response curves and pD2 values for the 
agonists in the absence and presence of FBF are shown in 
Figures 48 to 51, and Table 25, respectively.
ADRENALINE:
FBF had no effect on control I or control II
concentration-response curves to ADR in endometrium-free 
preparations (Figures 4 8 and 49) . Compared with control 
values, there were no significant differences in control I 
and control II pD2 values for ADR in the presence of FBF 
(Table 25) .
SALBUTAMOL:
FBF had no effect on control I and control II
concentration-response curves to SAL in endometrium—free 
preparations (Figures 50 and 51) . In control II
experiments, SAL produced a complete inhibition of the Ach- 
induced contraction. Compared with control values, there 
were no significant differences in control I and control II 
pD2 values for SAL, in the presence of FBF (Table 25).
Endometrium-removal produced a right-ward shift in ADR 
and SAL concentration-response curves, and decreased the 
maximum degree of inhibition (ADR only).
Cyclo-oxygenase inhibition had no effect on ADR and 
SAL responses in control I and control II experiments in
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FIGURE 48: Log. concentration response curves to Adrenaline 
in the rat isolated uterus in 1 day post partum:
Controls, endometrium free, and in presence of flurbiprofen 
(FBF, 10"5 m ). Number of observations in brackets.
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FIGURE 49: Log. concentration response curves to Adrenaline 
in the rat isolated uterus in 1 day post par turn endometrium free, 
Control II = ADR, in presence of AZA (10"® M), DMI (1Q“& M) and 
NMN (10“6 M): in presence of AZA (10“6 M), DMI (10“6 M), NMN
(10"® M) and FBF (10"5 M). Number of observations in brackets.
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FIGURE 50: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 1 day post partum: Controls 
endometrium free, and in presence of flurbiprofen (FBF, 10” 5 m ) 
Number of observations in brackets.
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FIGURE 51: Log. concentration response curves to Salbutamol 
in the rat isolated uterus in 1 day post partum endometrium free, 
Control II = SAL, in presence of AZA (10~° M), DMI (10~6 m) and * 
NMN (10"6 M): in presence of AZA (10-® M), DMI (10”6 m ),
NMN (10"6 M) and FBF (10“  ^M). Number of observations in 
brackets.
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Table 25:
Effect of Flurbiprofen (FBF, 10" ^ M) on Adr and Sal 
potencies, in endometrium-free uteri from one-day 
post partum animals (pD2 values).
Potency (pD2)
Drug Experiment After FBF
Adr Control I 
Control II
7.52 ± 0.34 (6) 
7.40 ±0.21 (6)
7.70 ± 0.33 (6)
7.70 ± 0.03 (6)
Sal Control I 
Control II
7.10 ±0 .34  (6) 
7.7Q ± 0.09 (6)
7.10 ± 0 .38  (6) 
7.77 ± 0.08 (6)
Values are m ean ± S.E.M., n  = num ber of observations.
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uteri from which the endometrium had been removed.
(M) ADENOSINE 3 15 1 CYCLIC MONOPHOSPHATE ASSAY EXPERIMENTS 
IN UTERI FROM NON-PREGNANT AND PREGNANT ANIMALS 
There is evidence that both the ovarian hormones and 
prostaglandins can alter cAMP metabolism in the rat uterus 
(Kishikawa, 1981; Krall et al.. 1984). Since the results
obtained so far indicate that adrenoceptor agonists may 
affect PG formation in uteri from non-pregnant and pregnant 
animals, the contribution of cAMP to the effects produced 
by a A  -adrenoceptor agonist, SAL, was investigated in a 
series of experiments.
Basal and SAL-stimulated cAMP levels were measured in 
preparations from the four phases of the oestrous cycle and 
from 20-day pregnant animals (with and without 
endometrium).
(i) cAMP LEVELS IN UTERI FROM THE FOUR PHASES OF THE 
OESTROUS CYCLE 
BASAL cAMP LEVELS 
The basal cAMP levels in uteri from proestrus, 
oestrus, metoestrus and dioestrus are shown in Figure 52. 
There were no statistically significant differences in 
basal cAMP content in the four phases, which lay in the 
range 100-150 pmol/g wet weight.
EFFECT OF SAL ON cAMP LEVELS:
The effects of SAL on cAMP level in uteri from the
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FIGURE 52: Effect of flurbiprofen (FBF) on basal cAMP levels 
(expressed as pmol/g wet weight of tissue) in the rat isolated 
uterus in proestrus, oestrus, metoestrus and dioestrus.
Open columns = controls; hatched columns = in presence of FBF 
(10“5 m). Number of observations in brackets.
four phases of the oestrous cycle are shown in Figures 53 
to 56. SAL (10 9 M - 10 5 M) produced a concentration- 
dependent increase in uterine cAMP content over the basal 
levels in proestrus (Figure 53), oestrus (Figure 54),
metoestrus (Figure 55) and dioestrus (Figure 56).
EFFECT OF A CYCLO-OXYGENASE INHIBITION ON cAMP LEVELS
Prostaglandins have been shown to alter cAMP
metabolism in the rat uterus (Krall et al. . 1984). Thus
the effect of cyclo-oxygenase inhibition on basal cAMP 
levels was examined in a series of experiments. The
effects of FBF (10~ 5 M) on basal cAMP levels are shown in 
Figure 52. FBF did not change the basal levels of cAMP. 
There were no significant differences in cAMP content in 
the presence of FBF in any phase of the cycle.
EFFECT OF SAL ON CAMP LEVELS IN UTERI PRETREATED WITH A 
CYCLO-OXYGENASE INHIBITOR
In a series of experiments, the effect of SAL (10“ 9  M 
- 10- 5  M) was examined in preparations pretreated with FBF 
(10“ 5  M) . In the presence of FBF, SAL produced 
concentration-dependent increases in uterine cAMP content. 
In all phases the increases were not different from those 
in which prostaglandin formation had not been inhibited.
Basal cAMP levels and the increases induced by SAL 
^ 0 j- 0 similar in all four phases of the oestrous cycle. 
Cyclo-oxygenase inhibition had no effect on basal cAMP 
levels, nor on the ability of SAL to increase tissue cAMP
content.
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FIGURE 53: Effect of Salbutamol on basal cAMP levels 
(expressed as pmol/g wet weight of tissue) in the rat 
isolated uterus in proestrus5 in the concentration range 
(10~9 m to 10"5 M). Number of observations in brackets.
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FIGURE 54: Effect of Salbutamol on basal cAMP levels 
(expressed as pmol/g wet weight of tissue) in the^  
isolated uterus in oestrus, in the concentration 
range (10"9 M to 10“5 M). Number of observations in
brackets.
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FIGURE 55: Effect of Salbutamol on basal cAMP levels
(expressed as pmol/g wet weight of tissue) in the rat 
isolated uterus in metoestrus, in the concentration 
range (10”9 m to 10"^ M). Number of observations in 
brackets.
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FIGURE 56: Effect of Salbutamol on basal cAMP levels 
(expressed as pmol/g wet weight of tissue) in the rat 
isolated uterus in dioestrus, in the concentration 
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(ii) CAMP LEVELS IN UTERI FROM 2 0-DAY PREGNANT ANIMALS
BASAL CAMP LEVELS:
Basal cAMP levels were measured in uteri with and 
without the endometrial layer. cAMP concentrations (pmol/g 
wet weight) in uteri with and without endometrium are (mean 
± S.E.M.) 148 ± 1 3  (n = 4) and 146 ± 2 0  (n = 4) and did not
differ from those obtained in the oestrous cycle 
respectively. Endometrium-removal did not significantly 
affect basal cAMP content in the uterus.
EFFECT OF SAL ON cAMP LEVELS:
The effect of SAL on cAMP levels was measured in
— 9preparations with and without endometrium. SAL (10 M - 
10”5 M) produced concentration-dependent increases in 
uterine cAMP content over the basal levels in normal and 
endometrium free preparations (Figure 57) . The increase in 
cAMP levels produced by SAL in uteri from 20-day pregnant 
rats did not differ from that induced in uteri from the 
four phases of the oestrous cycle.
There was no significant difference in cAMP content 
between normal and endometrium-free uterine preparations.
Endometrium-removal did not alter basal tissue cAMP 
content neither did it affect the ability of SAL to 
increase uterine cAMP content.
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FIGURE 57: Effect of Salbutamol on basal cAMP levels
(expressed as pmol/g wet weight of tissue) in the rat 
isolated uterus in 20 day pregnant with and without 
endometrium in the concentration range (10 M  to 10 M) 
Open columns = normal and intact endometrium; hatched 
columns = endometrium-free. Number of duplicate 
observations in brackets.
CHAPTER 4 
DISCUSSION
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(A) RESPONSES TO ACETYLCHOLINE IN UTERI DURING THE OESTROUS 
CYCLE, PREGNANCY AND IN POST PARTUM ANIMALS
Uteri from rats undergoing the natural oestrous cycle 
and pregnancy, and in those from postpartum animals were 
contracted by Ach. Ach potency was similar in uteri under 
the different hormonal conditions indicating that a 
homogeneous population of muscarinic receptors which may 
not be influenced by the ovarian hormones exists in this 
preparation. During the oestrous cycle, the maximum tension 
developed in response to Ach varied being highest in 
oestrus, and lowest in dioestrus. In the oestrogen 
pretreated rats, Ach produced greater tension, than in 
naturally occurring oestrus. Tension developed in response 
to Ach in uteri from 2 0-day pregnant and one-day postpartum 
animals was approximately more than two-fold higher when 
compared with the effect observed during the oestrous 
cycle. The differences in tension developed to Ach may be 
due to the observed variation in thickness of uterine 
smooth muscle in non-pregnant^pregnant and postpartum 
states (Digges, 1980; Boyle & Digges, 1982a,b). A 
difference in calcium function is also possible since the 
weak tension in non-pregnant, pregnant and postpartum rats 
may be due to a limited calcium influx (Maruyama, Ochiai, 
Tokutome, Hachiya & Umazume, 1986; Matsuzawa, Masahashi,
Kihira & Tomita, 1987) .
164
(B) RESPONSES TO ADRENOCEPTOR AGONISTS IN THE OESTROUS 
CYCLE AND AFTER OESTROGEN PRETREATMENT 
NA, ADR, and SAL produced inhibitory responses in 
proestrus, oestrus, metoestrus and dioestrus. Antagonism 
of the Ach-induced contraction by the adrenoceptor agonists 
is physiological, and is mediated via fa -adrenoceptor 
stimulation (Krall et al. , 1978; Boyle & Digges, 1982a;
Acritopoulou-Fourcroy et al. , 1985; Ohia & Boyle, 1987).
The fa -adrenoceptor population in the rat uterus is 
predominantly of the fa 2-subtype (Levy & Apperley, 1978; 
Johanssen, Andersson & Wikberg, 1980; Ohia & Boyle, 1987), 
but fa -j.” and fa 2 “a<3 renoceptors have been shown to co­
exist in oestrogen dominated uteri (Johanssen et— al.. , 1980, 
Nahorski, 1981) . The potencies displayed by NA, ADR and 
S^L in the present study are similar to those reported by 
other workers (Boyle & Digges, 1982a; Ohia, 1986, Ohia & 
Boyle, 1987). Thus supporting the above classification of 
/-adrenoceptors in the rat uterus during the oestrous cycle.
For each adrenoceptor agonist both the degree of 
inhibition and potency varied throughout the oestrous 
cycle. The variation could have been partially due to 
stimulation of ^  -excitatory receptors by NA and ADR, 
thereby causing a reduction in their P  -adrenoceptor 
mediated inhibition. At high concentrations, NA and ADR 
produced small motor responses in proestrus and oestrus, 
which were blocked by the <X -adrenoceptor antagonist, AZA. 
Similar AZA-sensitive motor responses have also been 
demonstrated in other studies (Boyle S Digges, 1982a; Boyle
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& Ohia, 1984). During proestrus and oestrus, there is an 
increase in £\ -adrenoceptor activity (Krall et al. , 1978; 
Acritopoulou-Fourcroy et al., 1985; Acritopoulou-Fourcroy & 
Marcias-Collado, 1988). Thus, it would seem that ^  -
adrenoceptor activity in the uterus is associated with 
conditions of oestrogen dominance, since oestrogen levels 
are high during proestrus and oestrus (Brenner & West, 
1975; Spaziani, 1975). In the presence of AZA, the maximum 
degree of inhibition produced by NA was enhanced in 
proestrus, oestrus and dioestrus. Enhancement of NA 
inhibitory effects in the rat uterus by 0( -adrenoceptor 
antagonists has also been shown by other workers (Brooks et 
al., 1965; Acritopoulou-Fourcroy et al.. 1985).
AZA also produced paradoxical shifts in ADR 
concentration-response curves to the right (oestrus and 
dioestrus), at the lower concentrations. Non-specific 
excitatory effects of AZA (Qayum & Yusuf, 1977) and other 
CK-adrenoceptor antagonists such as phentolamine and 
tolazoline (Tothill, 1967; Paton, 1968) have also been 
described. It thus appears that the rightward shifts 
caused by AZA may be explained in terms of a non-specific
stimulant action (Ohia, 1986).
Despite the non-specific effect produced by AZA, it 
can be concluded that there are 0< -excitatory receptors 
in the rat uterus which can be activated by NA and ADR. 
<X -adrenoceptors appear to contribute to the variations 
seen with NA and ADR but not SAL. It seems, therefore,
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that other factors may be involved in the observed 
differences i-n uterine response to adrenoceptor agonists 
during the oestrous cycle.
The concentration of adrenoceptor agonists at receptor 
sites is regulated by uptake processes into neuronal and 
extraneuronal tissue (Gillespie, 1973; Iversen, 1973; La 
Bella, 1985) . The possible role of these removal 
mechanisms in the variation in uterine response to 
adrenoceptor agonists was investigated in the presence of a 
neuronal uptake inhibitor (DMI), and an extraneuronal 
uptake inhibitor (NMN) . DMI and NMN shifted the 
concentration-response curves elicited by all three 
agonists to the left and enhanced their maximum degree of 
inhibition. The increased sensitivity induced by blockade 
of agonist sites of loss has been described as deviation 
supersensitivity (Fleming, 1975; Guimaraes & Trendelenburg,
1985) . Although DMI and NMN shifted adrenoceptor agonists 
concentration response curves to the left, corresponding 
increases in their values were not achieved in all
cases. One possible explanation could be that in addition 
to the observed leftward shifts, there was an increase in 
the maximum degrees of inhibition elicited by the agonists. 
Both changes in agonists response may serve to conceal 
alterations in their P^2 values induced by uptake 
inhibition.
The increased maximum response to agonists observed in 
the presence of the uptake inhibitors has also been 
demonstrated in the rat vasa deferentia (Kenakin, 1980,
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1984) . Since the rat uterus has a sparse adrenergic 
innervation (Silva, 19 66) , extraneuronal uptake may be more 
important than neuronal uptake in the disposal of 
catecholamines. In support of this view, Boyle & Digges 
(1982a) showed that inhibition of the extraneuronal process 
alone produced effects similar to blocking both neuronal 
and extraneuronal uptake processes. However, in the rat 
atria and vasa deferentia, Morton (1987) could not find any 
relationship between the density of adrenergic innervation 
and the degree of extraneuronal uptake confirming the 
earlier observations of Gillespie (1973) .
In the present study and that by Ohia (1986) , 
inhibition of the uptake processes produced greater effects 
(in terms of shifts in agonists concentration-response 
curves and increases in the maximum degree of inhibition) 
than blockade of C>( -excitatory adrenoceptors. Removal 
mechanisms may, therefore, play a more important role than 
CX,-adrenoceptor activity in the observed variation in 
uterine response during the oestrous cycle.
A series of experiments was performed in the presence 
of AZA, DMI and NMN in order to ensure that an effect on 
^  -adrenoceptors uncomplicated by CK —adrenoceptor activity 
was being observed. In the presence of the combined 
antagonists, the maximum degrees of inhibition produced by 
NA, ADR and SAL were increased in all phases of the 
oestrous cycle. Except for ADR, agonists concentration- 
response curves were also shifted to the left. The effects
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produced by the combined antagonists were similar to those 
achieved in the presence of uptake inhibitors alone, again 
supporting the view that agonists removal mechanisms are 
more important than c< -adrenoceptor activity. Since the 
variation in uterine response to adrenoceptor agonists 
persisted even in the presence of AZA, DMI and NMN, it 
seems that 0\ -adrenoceptor activity and the removal 
mechanism may only account in part for the observed 
differences.
There is evidence that ovariectomy enhanced uterine 
inhibitory response to catecholamines suggesting a role for 
the ovarian hormones in the observed variation in their 
action during the oestrous cycle (Ohia, 1986; Ohia & Boyle, 
1987). In the present study, the role of ovarian hormones 
was further investigated using a different model. Animals 
were pretreated with doses of oestradiol in order to induce 
oestrus and the effects of SAL re-examined alone and in the 
presence of AZA, DMI and NMN in order to compare the 
effects of the removal mechanisms in uteri from oestrogen 
pretreated animals with those in natural oestrus. When 
compared to effects observed in natural oestrus, uteri from 
oestrogen pretreated animals were more sensitive to the 
inhibitory action of SAL. Interestingly, the combined 
antagonists had no effect on the SAL response in uteri from 
oestrogen pretreated animals. One possible explanation of 
the enhanced response to SAL alone could be that high 
levels of oestrogen inhibit the extraneuronal uptake of SAL 
leading to an enhancement of its action. Indeed, SAL may
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be a substrate for the removal mechanisms in the rat uterus 
since its effect during the oestrous cycle was also 
potentiated by DMI and NMN (Ohia, 1986; present study).
The ovarian steroid used in this study has been shown 
to be a potent inhibitor of the extraneuronal uptake 
(Iversen & Salt, 1970; Salt, 1972). The lack of effect by 
the combined antagonists may, therefore, be due to the fact 
that uptake inhibition produced by oestradiol is maximal.
The finding that oestrogen pretreatment altered 
uterine response to SAL supports the view that the ovarian 
hormones may play a role in the observed variation in 
response to adrenoceptor agonists. Ovarian hormonal 
effects on adrenoceptor agonists responses did not appear 
to involve a direct action on adrenoceptor (Ohia & Boyle, 
1987). It seems more likely that the ovarian hormones 
affected some intracellular processes such as intramural 
prostaglandin production (Ham et al. , 1975; Sterin—Speziale
et aJL., 1980; Wilson, 1983 ; Gimeno & Gimeno, 1984) or
calcium utilization (Batra, 1986; Ishii, Kano & Ando,
1986) , which in turn would account for the variation in 
uterine response to the adrenoceptor agonists.
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(C) EFFECT OF ADRENOCEPTOR AGONISTS ON INTRAMURAL 
PROSTAGLANDIN PRODUCTION
Evidence from biochemical studies reveal that 
catecholamines can stimulate cyclo-oxygenase in tissue 
homogenates and isolated cells (Egan et al. , 1978; Baumann
et a l . , 1979). There is evidence that adrenoceptor
agonists may interact with the cyclo-oxygenase pathway 
leading to prostaglandin production in rat uteri in the 
different hormonal conditions of the oestrous cycle, and in 
the absence of the hormones following ovariectomy (Boyle & 
Ohia, 1985a, b; Ohia, 1986; Chaud et_al., 1986). In the
present study, the possible effects of adrenoceptor 
agonists on uterine prostaglandin production has been 
further investigated. The effects of the cyclo-oxygenase 
inhibitor, FBF, were examined on SAL responses in uteri 
from the four phases of the oestrous cycle. Both Control I 
and Control II studies were performed as described 
previously. FBF shifted SAL Control I and Control II 
concentration-response curves to the left and enhanced the 
maximum degree of inhibition in proestrus, oestrus (Control 
I only), metoestrus and dioestrus. After FBF SAL produced 
a complete inhibition of the Ach motor response in all 
phases. There was a corresponding increase in SAL potency, 
but it did not reach significance in all experiments. This 
failure may be due to the fact that in addition to the 
observed leftward shifts in SAL concentration-response
inrrease in the maximum degree of curves, there was an increase
. . .  a c observed earlier with the uptakeinhibition. As onserveu
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inhibitors, changes in potency may be occurring but are 
concealed by the increased intensity of SAL response in the 
presence of FBF. Similar observations were made by Ohia 
(1986) for the effects of FBF on SAL response during the 
oestrous cycle.
Since FBF enhanced SAL responses during the oestrous 
cycle and uteri from oestrogen pretreated animals are more 
sensitive to the inhibitory effects of this amine, it was 
considered of interest to examine the effect of cyclo- 
oxygenase inhibition on the responses produced by ^  -
adrenoceptor agonists, SAL, ISO and ISOX. FBF enhanced 
uterine inhibitory responses to SAL and ISO, but had a 
lesser effect on ISOX response. Thus cyclo-oxygenase 
inhibition also enhanced -adrenoceptor agonists
inhibitory responses in uteri from oestrogen pretreated 
animals.
Arachidonic acid is located predominantly in the 2- 
position of phospholipids and its release occurs by 
hydrolysis which is controlled by phospholipase A2 . The 
fact that intracellular levels of arachidonic acid are 
extremely low suggests that phospholipase A2 activation 
represents a rate limiting step in the production of 
eicosanoids (Chang, Musser & McGregor, 1987). A series of 
experiments was performed in order to investigate the 
effect of phospholipase A2 inhibition by Quinacrine on SAL 
response in uteri from oestrogen pretreated animals. 
Quinacrine enhanced uterine inhibitory response to SAL
which would suggest that products of the cyclo-oxygenase 
and lipooxygenase pathways may be involved in the $  
adrenoceptor agonist effect. However, Ohia (1986) showed 
that BW 755C (a dual inhibitor of cyclo-oxygenase and 
lipooxygenase activities) produced effects similar to those 
elicited by FBF indicating that products of the 
lipooxygenase pathway i.e. leukotrienes are not involved in 
adrenoceptor agonist responses.
The blockade produced by cyclo-oxygenase inhibitors 
such as indomethacin and aspirin has been shown to be 
partly reversed by arachidonic acid in the guinea-pig 
(Takei & Moritoki, 1987) and human (Quaas, Goppinger & 
Zahradnik, 1987) uterus. Thus the ability of arachidonic 
acid to reverse the effects elicited by FBF was tested in a 
series of experiments. FBF enhanced SAL inhibitory 
response in uteri from oestrogen pretreated animals, but 
this effect was unaffected by arachidonic acid. It seems, 
therefore, that in the rat uterus, effects produced by the 
cyclo-oxygenase inhibitor, FBF, are irreversible.
The possible involvement of prostaglandins in the 
inhibitory response produced by adrenoceptor agonist was 
investigated in uteri from late pregnancy. Both Control I 
and Control II experiments were performed for ADR and SAL 
in the absence and presence of FBF. In 2 0-day pregnant 
rats the maximum response to ADR and SAL in Control I never 
exceeded 60% inhibition of the Ach induced contraction, 
while in Control II ADR reached 80% and SAL 90% inhibition.
Thus in the Control I ADR was more effective in the
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pregnant rat than in the non-pregnant rat where inhibition 
never exceeded 45% of the Ach induced contraction although 
the degree of inhibition varied throughout the oestrous 
cycle. For SAL, the differences between the pregnant and 
non-pregnant animals were less marked, and SAL produced 65% 
inhibition in oestrus and 100% inhibition in metoestrus. 
The pD 2 values for ADR and SAL did not differ between the 
two groups of animals.
Since adrenoceptor agonists responses were altered by 
FBF treatment in uteri from non-pregnant and pregnant rats, 
a series of experiments was carried out to determine if the 
same relationship existed in preparations from one-day 
post-partum animals. Both Control I and Control II studies 
were performed for ADR and SAL in the absence and presence 
of FBF.
In one day post partum rats the maximum response to 
ADR in Control I never exceeded 95%, while in Control II 
around 90% inhibition of the Ach induced contraction, that 
produced by SAL in Control I reached 95% and in Control II 
100%. Thus in the post partum rat, both ADR and SAL are 
more effective inhibiting Ach induced contractions than in 
either 20 day pregnant or non-pregnant rats.
FBF shifted agonists Control I and Control II 
concentration-response curves to the left and enhanced 
their maximum degree of inhibition. There were
corresponding increases in agonists potencies which did not 
reach significance in all experiments. Thus, intramurally
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generated prostaglandins may also be involved in uterine 
response to adrenoceptor agonists in uteri from 20-day 
pregnant animals. FBF also shifted SAL concentration- 
response curves to the left, but had no effect on ADR 
response. ^  uteri from 1 day post-partum animals
Generally, effects elicited by FBF in uteri from post 
partum animals were less than those observed in non­
pregnant and pregnant ones. It is unclear why cyclo- 
oxygenase inhibition had little or no effects on ADR 
response in uteri from post partum animals. One possible 
explanation for the reduced effects produced by cyclo- 
oxygenase inhibition may be that uteri under this condition 
have a lower basal prostaglandin activity than in those 
from pregnant animals (Harney, Sneddon & Williams, 1974) . 
However, the finding that SAL responses were enhanced by 
the cyclo-oxygenase inhibitor, FBF, would tend to support 
the view that endogenous prostaglandins are involved in 
adrenoceptor agonists effects in post partum uteri.
A series of experiments was performed in order to 
assess the contribution of the endometrium in the 
interaction between adrenoceptor agonist and the cyclo- 
oxygenase pathway. Uteri from rats in late pregnancy and 
post partum were employed for this study because it is 
easier to remove the endometrium from these preparations as 
compared to those from non-pregnant animals. Both Control 
I and Control II studies were carried out for ADR and SAL 
in the absence and presence of FBF. Endometrium removal 
caused a reduction m  uterine response to ADR and SAL, with
the effects greater in one-day post partum animals than in 
20-day pregnant animals. The mechanism responsible for the 
reduction in adrenoceptor agonist response in endometrium- 
free uteri is unclear. FBF had no significant effect on 
ADR and SAL responses in endometrium-free preparations from 
20-day pregnant and one-day post partum animals. It thus 
seems that the endometrium could play a role in the 
interaction between adrenoceptor agonists and the cyclo- 
oxygenase pathway. The present finding appears consistent 
with previous reports from biochemical studies that the 
endometrium could be a major source of prostaglandins in 
the rat uterus (Campos et al., 1980; Brown & Poyser, 1985).
In summary, cyclo-oxygenase inhibition enhanced 
uterine inhibitory responses to adrenoceptor agonists in 
uteri from animals in the four phases of the oestrous cycle 
and after oestrogen pre-treatment. Inhibitory responses 
elicited by the adrenoceptor agonists in uteri from late 
pregnancy and in those from post partum animals were also 
enhanced by the cyclo-oxygenase inhibitor. The effect 
produced by the cyclo-oxygenase inhibitor was, however, not 
reversed in the presence of exogenous arachidonic acid. 
Cyclo-oxygenase inhibition had no effect on adrenoceptor 
agonists responses in endometrium-free uteri from late 
pregnancy and in those from post partum animals. 
Inhibition of phospholipase A2 activity by Quinacrine also 
enhanced adrenoceptor agonists responses. The above 
results indicate that adrenoceptor agonists may interact
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with the cyclo-oxygenase pathway leading to prostaglandin 
production in uteri from non-pregnant, pregnant and post 
partum animals. Endogenous prostaglandins thus formed as a 
result of adrenoceptor agonists effects would then oppose 
the ji -adrenoceptor mediated inhibition. The endometrium 
seems to play a major role in the adrenoceptor agonist 
effect on intramural prostaglandin generation. The finding 
that phospholipase A 2 inhibition also altered uterine 
response to adrenoceptor agonist would tend to suggest that 
the availability of arachidonic acid for conversion to 
prostaglandins by cyclo-oxygenase may represent an 
important step in the process.
In support of results from the present study, 
involvement of prostaglandins in adrenoceptor agonists 
responses have also been shown in guinea-pig (Takei & 
Moritoki, 1987), sheep (Lye et al. . 1987) and pregnant
human (Quaas & Zahradnik, 1985; Wikland, Lindblom & 
Wigvist, 1985; Quaas et a l . . 1987) uterus. The
participation of prostaglandins in adrenoceptor agonists 
responses has been demonstrated in a vascular (Rubanyi & 
Vanhoutte, 1985) and non-vascular (Trachte, 1987) smooth 
muscle. The mechanism by which prostaglandin biosynthesis 
could be stimulated by adrenoceptor agonists is not well 
understood. There is evidence that the agonists may 
directly activate cyclo-oxygenase activity by acting as 
phenolic co-factors for the cyclo-oxygenase of arachidonic 
acid (Egan et al., 1978; Baumann et _al. , 1979). It may
also be possible that stimulation of cyclo-oxygenase could
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be an indirect event produced by activation of 
adrenoceptors. -adrenoceptors have been implicated in
uterine prostaglandin production in humans (Wikland et al., 
1985; Quaas et al. . 1987), while -adrenoceptors may
mediate the process in sheep (Lye et al. , 1987) . In
contrast, both oi. - and &  -adrenoceptors may be involved 
in rat uterine prostaglandin production in the four phases 
of the oestrous cycle (Ohia, 1986) and in ovariectomized 
animals (Ohia, 1986; Chaud et al., 1986). The link between 
adrenoceptor activation and increased prostaglandin 
activity is unclear, but recent evidence suggests that GTP 
binding (G) proteins may be involved in the process (Reimer 
& Roberts, 1986; Burgoyne, Cheek & O'Sullivan, 1987; 
Axelrod, Burch & Jelsema, 1988). Axelrod et al (1988), 
proposed that upon activation of phospholipase A2 by a 
receptor-coupled G protein, arachidonic acid and its 
numerous biologically active metabolites are generated. It 
is feasible, therefore, that adrenoceptor agonists effects 
on prostaglandin production in the rat uterus could be 
achieved in two ways; (a) by a direct effect of the 
agonists on cyclo-oxygenase and/or (b) by an indirect 
action on cyclo-oxygenase activity via an effect on 
adrenoceptor-coupled G protein leading to activation of 
phospholipase A2 •
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(D) ROLE OF CAMP
An increase in cAMP accumulation has been shown to
(Meisheri, Diamond & McNeill, 1981; Marshall & Fain, 1985; 
Dokac, D'Albis, Janmot & Harbon, 1986; Tanfur & Harbon, 
1987). There is evidence that both oestrogen (Sandborn et 
al, 1973; Flandroy & Galand, 1978; Kishikawa, 1981) and 
prostaglandins (Vesin & Harbon, 1974; Vesin, Dokhac & 
Harbon, 1978, 1979; Dokhac et al. , 1986; Tanfin & Harbon,
1987) can alter cAMP production in the rat uterus. It is, 
therefore, possible that fi -adrenoceptor agonists, ovarian 
hormones and prostaglandins may interact at the level of 
cAMP formation. Changes in cAMP metabolism induced by 
these factors may partially account for the differences in 
uterine response to adrenoceptor agonists during the 
oestrous cycle.
The possible role of cAMP metabolism in the variation 
in uterine response to adrenoceptor agonists was 
investigated in a series of experiments. Basal and SAL- 
stimulated increases in uterine cAMP content were measured 
in proestrus, oestrus, metoestrus and dioestrus. Basal 
cAMP concentrations were similar in uteri from all four 
phases. SAL elicited a concentration-dependent increase in 
cAMP levels which were similar in all phases. The above 
results are consistent with the report by Ohia (1986, 1988) 
and suggest that the variation in uterine response to 
adrenoceptor agonists may not be due to effects of 
endogenous oestrogen on cAMP, and the differential action
accompany activation in the rat uterus
of the agonists on cAMP production during the oestrous 
cycle.
Since exogenous prostaglandin E2 can affect uterine 
cAMP production, experiments were performed to determine 
the possible effects of intramurally generated 
prostaglandins on basal cAMP formation. The basal levels 
of cAMP did not differ significantly in the four stages of 
the oestrous cycle. FBF had no effect on basal cAMP 
content in the four phases of the oestrous cycle indicating 
that in physiological concentrations, prostaglandins may 
not affect uterine cAMP production. A similar effect has 
been reported by Tanfin & Harbon (1987) who found that 
basal cAMP levels in the pregnant rat uterus were unaltered 
by aspirin, a cyclo-oxygenase inhibitor.
Based on the hypothesis that exogenous prostaglandin 
E2 may antagonize uterine inhibitory response to ft - 
adrenoceptor agonists by a desensitizing action on 
adenylate cyclase (Krall et a l . , 1984), a series of
experiments was performed to investigate the role of 
endogenous prostaglandins on SAL-induced cAMP accumulation. 
FBF had no effect on SAL-stimulated cAMP levels in uteri 
from the four phases of the oestrous cycle. It thus seems 
that the site of interaction between the adrenoceptor 
agonists and the endogenous prostaglandins generated by 
them may not be at the level of cAMP formation. Tanfin and 
Harbon (1987) also found that aspirin did not affect ISO- 
induced increases in uterine cAMP content.
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The results presented above so far show that 
endometrium removal caused a reduction in adrenoceptor 
agonists responses in uteri from late pregnancy and post 
partum. The contribution of the endometrium to SAL-induced 
increases in uterine cAMP content was, therefore examined 
in a series of experiments. Basal and SAL-stimulated cAMP 
levels were measured in uteri from 20-day pregnant animals 
in the presence and absence of endometrium. Basal cAMP 
levels were similar in both normal and endometrium-free 
preparations. SAL produced a concentration-dependent 
increase in uterine cAMP content which was similar in both 
normal and endometrium-free preparations. Thus, it would 
appear that absence of the endometrium does not affect the 
ability of SAL to increase uterine cAMP content. An effect 
on tissue cAMP metabolism may, therefore, not account for 
the observed reduction in uterine response to adrenoceptor 
agonists in endometrium-free preparation.
In conclusion, presence of a heterogeneous population 
of adrenoceptors, avid removal mechanisms into neuronal and 
extraneuronal sites, and the ovarian hormones contributed 
to the observed variation in uterine response to 
adrenoceptor agonists during the oestrous cycle. Agonist 
effects on intramurally generated prostaglandins could also 
be involved in the observed varition and may indeed, play a 
crucial role since it affected agonists response in uteri 
from non-pregnant, pregnant and post partum animals. 
Intracellular cAMP was the mediator of uterine response to 
adrenoceptor agonists in preparations from non-pregnant and
pregnant animals. However, changes in tissue cAMP 
metabolism did not appear to be of major importance in the 
variation in uterine response to adrenoceptor agonists 
during the natural oestrous cycle. The present study thus 
provides further pharmacological evidence for the 
involvement of several factors in rat uterine response to 
adrenoceptor agonists.
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